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DE STROOMVERSNELLING 
In het matrix van genetica zweven ze rond 
De oplossingen tot het raadsel, wat een vondst! 
Op zoek naar de druppel 
Die een zee van antwoorden geven 
Tot nu nog door meerdere onbegrepen 
 
Als Sherlock van ouds, gewapend met meer dan een vergrootglas 
met data, pipet en microscoop; ook geduld komt handig te pas 
juist of fout, herhaaldelijk bewezen 
blijven denken en betwijfelen, blijven vragen en lezen 
Ineens wordt het duidelijk, nog eentje opgelost! 
Euforie! …en dan terug naar de volgende post 
 
Student en leermeester, een gans team erbij 
Wij zullen het vinden, zij-aan-zij 
Stroomop of in stroomversnelling, blijven gaan, wij zijn er bijna! 
 
En nu, plots, stopt mijn ‘officiële’ zoektocht… 
‘Neen’, klinkt de chorus in mijn hoofd: ‘Het is maar juist begonnen!’ 
         Jacoba J. Louw, 2017 
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SUMMARY 
 
The main aim of this thesis was to evaluate the application of a powerful genetic tool, Next 
Generation Sequencing, to contribute to the understanding of genetics in congenital heart defects 
(CHD) and congenital cardiomyopathies. We specifically used Whole Exome Sequencing (WES), 
which analyses the protein coding parts of the human genome, in two distinct clinical groups: 
sporadic syndromic cases and small families with two affected siblings.  
 
In the sporadic syndromic cases a de novo mutation was most likely and analysis was done by trio 
analysis (WES in the patient and both parents) and compared to index-only analysis (WES only in 
the patient). Here we could conclude that trio analysis outperforms index-only analysis as filtering 
was more efficient and resulted in a higher percentage of cases being solved (Chapter 3). We 
reported the first intragenic mutation in MEIS2 which further confirmed the important role of this 
gene in normal development (Chapter 3.1). 
In the families with two siblings sharing a similar phenotype, autosomal recessive inheritance was 
most likely. (Chapter 4). Linkage analysis was combined with WES and resulted in solving two 
families with a rare, neonatally lethal, cardiomyopathy. In the first family a homozygous mutation 
in a known gene (ALMS1) for Alström syndrome was found. The cardiomyopathy in this family 
represents the extreme end of the cardiac spectrum in this syndrome (Chapter 4.1). In the second 
family a compound heterozygous mutation was found in a gene (KIF20A) which has not been 
associated previously with human pathology. To prove the pathogenicity we performed 
additional functional tests, including animal studies in zebrafish which resulted in a progressive 
and lethal cardiomyopathy phenotype (Chapter 4.2). Discovery of these two genes open a new 
mechanism for future research in linking cardiomyopathies to genes involved in cytokinesis. 
 
Based on our experience as well as current available literature we formulated guidelines for 
genetic diagnosis in CHD for cardiologists and geneticists. Classifying CHD into four clinical groups 
based on familial and syndromic characteristics necessitates a different strategic approach. In the 
last chapter we also addressed the crucial economic aspects and limitations of WES (Chapter 5). 
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SAMENVATTING 
 
Het belangrijkste doel van dit proefschrift was om inzicht te verkrijgen in het genetisch landschap 
van aangeboren hartafwijkingen en congenitale cardiomyopathieën door de toepassing van een 
krachtige genetische tool, Next Generation Sequencing. Wij verrichtten analyse door Whole 
Exoom Sequencing (WES) - het eiwit coderende deel van het menselijk genoom - in twee 
afzonderlijke klinische groepen: sporadische syndromale patiënten en kleine families met 
minstens twee siblings met hetzelfde fenotype. 
 
In de sporadische syndromale patiënten was een de novo mutatie het meest waarschijnlijk en 
werd de analyse uitgevoerd door trio analyse (WES in de patiënt en beide ouders) en vergeleken 
met index-only analyse (WES alleen bij de patiënt). Hieruit concludeerden we dat trio analyse 
beter functioneert gezien de filtering efficiënter was en frequenter leidde tot het vinden van een 
causaal genotype (Hoofdstuk 3). We publiceerden de eerste intragene mutatie in MEIS2 die de 
cruciale rol van dit gen in normale ontwikkeling verder bevestigd (Hoofdstuk 3.1). 
In families met siblings met een vergelijkbaar fenotype, was een autosomaal recessieve 
overerving het meest waarschijnlijk (Hoofdstuk 4). Koppelingsanalyse werd met WES 
gecombineerd en leidde tot het vinden van een causaal genotype in twee families met een 
zeldzame, neonataal lethale, cardiomyopathie. In de eerste familie werd een homozygote 
mutatie in een bekend gen (ALMS1) voor Alström syndroom gevonden. De cardiomyopathie in 
deze familie past bij het uiterste spectrum van het cardiale fenotype van dit syndroom (Hoofdstuk 
4.1). In de tweede familie werd een samengesteld heterozygote mutatie in een gen (KIF20A) 
gerapporteerd dat nooit eerder werd geassocieerd met humane pathologie. Om het causale 
aspect verder te verifiëren werden bijkomende functionele studies uitgevoerd, inclusief een 
dierenmodel in zebravisjes die resulteerde in een progressieve lethale cardiomyopathie 
(Hoofdstuk 4.2). De ontdekking van deze twee genen opent een nieuw mechanisme voor 
toekomstig onderzoek door het koppeling van cardiomyopathieën aan mutaties in genen die 
betrokken zijn bij celdeling of mitose. 
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Wij hebben, gebaseerd op onze ervaring en de beschikbare literatuur, richtlijnen voor genetische 
diagnose bij aangeboren hartafwijkingen geformuleerd voor cardiologen en genetici. Op basis van 
syndromale en familiale gegevens onderscheiden we vier klinische groepen, die een andere 
strategie in genetisch diagnostiek voor CHD vereisen. Ten slotte werden de economische 
aspecten en beperkingen van WES die cruciaal zijn in het diagnostisch proces samengevat 
(Hoofdstuk 5). 
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INTRODUCTION 
Congenital heart defects (CHD) are structural anomalies of the heart arising from abnormal 
formation of the heart or major blood vessels. At least 18 distinct types of congenital heart defects 
are recognized, with many additional anatomic variations. The majority of CHD are structural 
defects and have an incidence of 7,5/100 live births, if trivial lesions such as small muscular 
ventricle septal defects are included, making it the most common birth defect [1]. Moderate to 
severe CHD with functional consequences occur in 6-8 out of 1000 live births (19/1,000 live births 
if the potentially serious bicuspid aortic valve is included) [1, 2]. These structural defects are the 
result of abnormal embryonic heart development and can be anatomically classified into 
abnormalities of the septa, the heart valves, and inflow or outflow tract of the heart. These 
structural defects most often have functional consequences, but of varying degree and 
significance. Some structural defects do not have important functional significance in early life 
such as the aortic valve with two leaflets, the prolapsing mitral valve, a small persistent patency 
of the arterial duct, small septal defects and patency of the oval foramen. This group might also 
include structural defects which resolve without ever becoming clinically manifest, such as small 
muscular ventricular septal defects and atrial septal defects or peripheral pulmonary stenosis. 
Consideration of these lesions is important because they are common, and might inflate a 
prevalence estimate. This is also influenced by the surveillance and likelihood of diagnosis which 
differs greatly in developed and developing countries. 
Cardiomyopathies (CM) are a different entity which are defined as primary myocardial disorders 
in which the heart muscle is structurally and functionally abnormal, in the absence of other causes 
such as CHD [3]. The annual incidence of pediatric cardiomyopathy is low, 3-6 per 1 million 
children, with the highest incidence in the first year of life [4, 5]. Four major types of CM are 
distinguished, i.e., hypertrophic, dilated, restrictive, and arrhythmogenic right ventricular 
cardiomyopathy (ARVC) [6], but there is considerable etiologic and phenotypic overlap. 
Previously, hypertrophic CM was described as a sarcomeric disease, with mutations encoding 
contractile proteins of the cardiac sarcomere, and pathogenic mutations have been detected in 
11 genes encoding for sarcomeric proteins. Most mutations, around 80% are detected in MYH7 
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(β-myosin heavy chain) and MYBPC3 (myosin-binding protein C) [7]. The other 9 genes account 
for far fewer cases of HCM and include troponin T and I, regulatory and essential myosin light 
chains, titin, α-tropomyosin, α-actin, α-myosin heavy chain, and muscle LIM protein. There is 
considerable intragenic heterogeneity, with >400 individual mutations which have been 
identified.  There is also considerable variable expressivity, even within families, which is most 
probably to the influence of modifier genes and environmental factors [7]. Pathogenic mutations 
have also been detected in HCM in genes encoding for Z-disk, sarcoplasmic reticulum and plasma 
membrane proteins. Interestingly, mutations in sarcomeric and Z-disk genes have also been 
identified in patients with DCM and RCM and desmosomal protein genes in DCM, RCM and ARVC 
[7]. 
Reaching an etiological diagnosis is important for counselling on recurrence risks for future 
siblings or offspring. When no exact cause can be identified, predictions on recurrence risk for 
additional children in the family or future offspring is mostly based on empirical risks, without 
knowledge of the true underlying genetic mechanism [8]. Whereas recurrence risks for congenital 
heart disease usually are low, a large number of individually rare genetic disorders exist that may 
carry a significant recurrence risk e.g. Noonan syndrome, Barth syndrome or 22q11.2 
microdeletion syndrome.  
Despite diagnostic and surgical advances, CHD remains a major cause of infant morbidity and 
mortality. Improved prenatal and neonatal diagnostics, as well as pediatric bypass surgery and 
percutaneous interventions prolong life expectancy. As more patients survive into adulthood, the 
burden of disease, and the requirements for resources, have also achieved greater importance. 
In addition, this has resulted in increased demand for genetic counselling of adults who have been 
treated for a CHD themselves, and reassessment of recurrence risk for CHD in offspring [9]. In 
infants and children, one of the major challenges is to predict the long-term prognosis, 
concomitant morbidities and societal impact. For instance, the prospects of patients diagnosed 
with a Tetralogy of Fallot (ToF) as an isolated cardiopathy or as part of a 22q11.2 microdeletion 
syndrome differ significantly. Not only do patients with a 22q11.2 microdeletion syndrome have 
a different life expectancy but they have a high incidence of intellectual disability (ID), psychiatric 
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manifestations and medical comorbidity, necessitating life-long surveillance [10-14]. Long-term 
prognosis is compromised especially in CHD with additional manifestations including ID. Detailed 
phenotyping and long-term follow-up of many different syndromes have led to clinical guidelines 
for optimized guidance and follow-up. For instance patients with Down syndrome need to be 
followed for concomitant hearing loss and thyroid disease [15, 16], children with Noonan 
syndrome often have short stature and Williams syndrome is associated with a characteristic 
behavioral phenotype.  
Over the past decades, a genetic revolution has taken place, which has largely been driven by 
technological advances. This has led to new insights in the function and structure of the human 
genome, and the identification of genes implicated a large number of genetic disorders.  This 
knowledge and technology has rapidly been translated into the clinic, to advance genetic 
diagnosis in individuals with congenital disorders, including certain categories of CHD. 
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GENETIC TOOLS 
The genetic tools available to study the structure and sequence of the human genome have 
changed considerably in the last 20 years. Traditionally, one distinguished cytogenetic versus 
molecular analyses, depending on whether one was studying the number and structure of 
chromosomes or individual genes, typically at the sequence level. However, with current 
technology, this distinction is often blurred.  
 
Cytogenetic techniques 
1. Karyotype 
This classical technique was introduced in 1955 to study the number and structure of 
chromosomes of a human eukaryotic cell. Over the years, the resolution has increased by 
chromosome banding techniques and prometaphase chromosome analysis. However, on 
average, the resolution of karyotyping is limited to fragments of 5-10 Megabases (Mb), containing 
on average 35-70 genes (Figure 2). A unique feature of karyotyping compared to other 
cytogenetic tools is that it permits the detection of balanced chromosomal anomalies, without 
associated loss of genetic material. Such balanced translocations may disrupt a gene and cause a 
congenital defect. As such, they present unique but rare opportunities to identify genes for 
specific disorders. Examples in the field of cardiogenetics include ELN and Supravalvular aortic 
stenosis [17], PROSIT240 and transposition of the great arteries [18] and the TAB2 gene and 
cardiac valve disorders [19].  
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Figure 2. Advances in genetic technology showing the differences in resolution and screening 
capacity for different tests in research and diagnostics. 
2. Fluorescence in situ hybridization  
Fluorescence in situ hybridization (FISH) is a cytogenetic technique developed in the early 1980s 
and used to detect and localize the presence or absence of specific DNA sequences.  Fluorescent 
probes are used which bind complementary sequences on the chromosome with a high degree 
of sequence complementarity. It is typically used to detect microdeletions, e.g22q11.2 
microdeletion syndrome or del7q11.2 (Williams syndrome). Moreover, an important advantage 
is the possibility to rapidly detect imbalances or aneuploidies in interphase nuclei, e.g. to confirm 
a suspected diagnosis of Down syndrome. Whereas FISH has a resolution at the single gene level, 
its application is typically limited to a few loci in one experiment. Therefore, FISH remains targeted 
at the detection of a suspected imbalance, based on clinical suspicion.   
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3. Microarray-based copy number variation (CNV) detection  
At the beginning of the 21st century, microarray analysis was introduced. It is a 
molecular technique used for detecting chromosomal copy number variations (CNV), a term used 
for small deletions (microdeletions) or duplications (microduplications). Two types of microarrays 
are used: oligonucleotide arrays for array comparative genomic hybridization (also called 
microarray-CGH, aCGH) and SNP-based microarrays. Microarrays combine the genome-wide 
screening capacity of karyotyping with the high resolution of FISH. It is now possible to detect 
small CNV’s including a single gene or even a few exons. This technology is currently used as a 
routine diagnostic test for patients with a developmental disorder including congenital 
malformations, dysmorphism and intellectual disability. Using array-CGH 15-20% of unknown 
syndromic cases are currently solved [20]. This technology has also been introduced in prenatal 
diagnosis of syndromic CHD’s in Belgium [21]. Microarray analysis additionally played a crucial 
role in the hunt for genes involved in CHD’s. Numerous genes have thus been identified, often 
through the identification of the smaller region of overlap in patients with similar phenotype, e.g. 
GATA4 on chromosome 8p23.1 [22], CHD7 in CHARGE syndrome [23] and NKX2.5 on chromosome 
5q35.1 [24]. 
 
4. MLPA 
MLPA (Multiplex Ligation-dependent Probe Amplification) is a multiplex PCR method that allows 
the quantitative detection of abnormal copy numbers for small regions (50-70 nt, typically exon 
level) of up to 50 different loci. It is known that for most monogenic disorders caused by loss-of-
function mutations, a small percentage of such mutations are small deletions or duplications (a 
single or a few exons) which typically escape detection by current sequencing techniques or by 
microarrays. Therefore MLPA is mostly used to complete gene sequencing to detect such small 
imbalances [25-27].  An example is the vast variety of mutations in the dystrophin gene (DMD) 
which lead to Duchenne and Becker muscular dystrophies. The dystrophin gene is the third largest 
human gene and spans 2.2 Mb and has 79 exons. Intragenic deletions account for 65% of 
mutations and duplications in 10%. The remaining 25% circa of DMD mutations are represented 
by small mutations, including point mutations (missense, nonsense), frameshifting, indels, and 
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other rare types (small inversion, complex small rearrangements, atypical deep intronic 
mutations) [26]. 
 
5. Sequencing technology 
Specific genes can be sequenced through Sanger sequencing, but this is laborious and costly to 
perform for multiple genes. More recently, next generation sequencing technology (NGS) was 
developed and allowed massive parallel sequencing. This made it possible to screen the coding 
parts (exons) of a large number of target genes (targeted panel) or of all genes (whole exome 
sequencing) in search of possible causative mutations.   
NGS has shifted the challenge from variant detection to variant interpretation: the new “bottle-
neck” is data analysis and interpretation. Sifting through the huge amount of data to find a 
pathogenic mutation in a known or novel gene is time consuming and strongly depends on 
existing knowledge. In addition, proof that a certain gene is a novel cause of a CHD may require 
lengthy functional studies, including animal models. This is not trivial, since the ultimate goal is 
translating this knowledge to the clinic, e.g. offering prenatal diagnosis. This has further led to 
indistinct borders between diagnostics and research. 
 
5.1. Next-Generation Sequencing Technologies 
Currently, we are witnessing a technological revolution of high-throughput massively parallel 
sequencing methods which allows us to determine the sequence of a large number of genes in 
one single analysis [28-30]. NGS technologies enable large-scale DNA sequencing, and have 
dramatically accelerated the genetic research and diagnostics, leading to a rapid increase in the 
delineation of novel genetic entities, as is shown in Figure 1 [31, 32].  
Many of the steps in NGS technology have been evolving rapidly, including sample preparation 
methods [33], sequencing machines and bioinformatics tools for NGS data processing, but this is 
beyond the scope of this introduction. 
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Figure 1. Growth in Number of Online Mendelian Inheritance in Man (OMIM) entries by Year. 
In the last two decades there has been a tremendous growth in the identification of genes for 
Mendelian disorders and identification of novel genetic disorders due to advances in genetic 
technology. Used with permission of Simon Sadedin (December 2015). 
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Depending on the number of genes resequenced, one can distinguish three different applications: 
(1) Sequence analysis of a predetermined set of candidate genes for a specific condition. For 
instance, panels of known genes causing CHD, CM, or arrhythmias. This is typically used as a 
diagnostic tool. In the Center for Human Genetics in Leuven, using targeted capture for 57 genes 
implicated in congenital heart defects, we have thus far identified potential causative mutations 
in 46% of analysed families with three or more affected individuals (n = 13 families) [24]. For more 
complex phenotypes (e.g. CHD associated with intellectual disability or multiple malformations) 
one can use a Mendeliome approach, a panel consisting of the approximately 6000 genes known 
to be involved in a genetic disorder.  
(2) Sequencing the coding sequences (exons) of all 20.000 human genes by Whole Exome 
Sequencing (WES). The exome encompasses around 1% of the human genome. WES have been 
used to identify point mutations, as well as small (<50 base pairs) insertions or deletions (indels) 
in exonic regions. WES is still essentially a research tool, but as mentioned previously, it is also 
being used in specific diagnostic settings.  
As a research tool, WES has achieved a major breakthrough in the identification of genes 
involved in developmental disorders, including CHD. Since the majority of severe sporadic CHD 
is caused by a de novo mutation, several researchers used WES in a trio (CHD proband-parent) 
analysis. This has resulted in the identification of several novel CHD genes [34-38]. Of interest, 
the genetic mechanism for many of these genes is not a loss-of-function but dominant negative 
or gain-of-function mutation which typically result from missense mutations, and affects crucial 
functional amino acid residues. Examples include Rasopathies [39-41] where simple dosage 
alterations as in the deletion or duplication of these genes do not result in the same phenotype, 
and therefore, previous genome-wide screening studies using CNV analysis failed to identify 
these genes as candidate genes for CHD.  
 (3) In Whole Genome Sequencing (WGS) the entire human genome (including the 99% not 
included by WES) is analysed, thus all coding and non-coding regions. WGS is still an emerging 
technology, partly due to the relatively high cost of sequencing, but mainly due to the 
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requirements of more sophisticated bioinformatics tools and computing infrastructure.  
 
GENETICS AND CLASSIFICATION OF CHD 
Gene identification for CHD still represents a major challenge, especially since the genetics of CHD 
is heterogeneous [42]. Not only can different genes be involved, also different inheritance 
patterns exist. From a clinical point of view, we can distinguish syndromic from non-syndromic 
forms depending on the presence of dysmorphism, additional major malformations and/or 
intellectual disability. A second characteristic is the familial history: sporadic or familial 
occurrence, and the pattern of inheritance.  These two characteristics allow us to define four 
different clinical categories of congenital cardiopathies (Figure 3): (A) sporadic syndromic CHD 
(22%) [43-45], (B) familial syndromic CHD (exceptional), (C) sporadic non-syndromic CHD (74%) 
and (D) familial non-syndromic CHD (4%). This distinction with regard to cardiopathies is a 
clinically useful lead to diagnosis, because each category requires a specific diagnostic approach 
but also with regard to further follow-up and guidance. Moreover, this distinction may aid 
directing the set-up of research towards the identification of novel genes.  
(A) Sporadic syndromic CHD  
This category mostly occurs as the result of a de novo mutation, either chromosomal (e.g. Down 
syndrome and deletion 1p36), or genomic disorders e.g. DiGeorge syndrome (22q11.2 
microdeletion syndrome) and Williams syndrome (del7q11.23) or monogenic such as Holt-Oram, 
Kabuki, Alagille and Noonan syndromes, chromosomal imbalances. 
(B) Familial syndromic CHD  
Autosomal dominant inheritance of a syndrome is only expected when the expression is 
compatible with survival and reproduction, which is rare. Affected siblings with normal parents is 
typically observed in autosomal recessive (e.g. Friedreich ataxia) or X-linked recessive inheritance 
(e.g. Barth syndrome).  
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(C) Sporadic, non-syndromic CHD 
This is the most commonly observed group, and is thought to have a multifactorial cause, i.e. the 
interaction of multiple genetic and environmental factors, each with a low risk. However, more 
recently, exome and copy number variation studies indicate that rare variants with a moderate 
effect are involved, at least in a small proportion of cases [46, 47].  
(D) Familial non-syndromic CHD 
Rarely, multiple affected individuals exist with recurrence of a same type of non-syndromic CHD. 
In most families, inheritance is autosomal dominant, and known genes include ELN, NKX2.5, 
GATA4, and NOTCH1. 
 
Figure 3. The genetics of CHD results in four different clinical categories: sporadic non-
syndromic (74%), sporadic syndromic (21%), familial non-syndromic (4%) and familial 
syndromic (exceptional <1%). 
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GENETIC STUDIES OF SYNDROMIC CHD AND CARDIOMYOPATHIES BY NGS 
In this study, we evaluated the use of NGS in the identification of the genetic cause in syndromic 
forms of CHD, both sporadic and familial. 
Sporadic syndromic cases with unknown cause 
Since the majority of known sporadic syndromes featuring a major malformation have a de novo 
AD cause, we hypothesized that also in those with an unknown cause, a de novo dominant 
mutation is present in a significant proportion. To identify causal mutations, exome sequencing 
using a trio approach (parents and child) was likely to be the most efficient way. Given the cost, 
we compared this to an index-only analysis.  
Familial syndromic congenital heart defects  
When two or more siblings in the same family have the same CHD, the most likely explanation is 
a multifactorial inheritance. However, certain very rare and specific (syndromic) phenotypes may 
have a monogenic cause, but no obvious candidate genes exist. This occurs when the combination 
of distinct anomalies observed in the siblings does not fit a known entity, and thus constitute a 
new syndrome. Alternatively, the cardiac phenotype is unique, e.g. an unclassified type of CM. In 
these families, the inheritance pattern is most likely autosomal recessive (AR) and sometimes X-
linked. Germline mosaicism in one parent for an AD inherited disorder should also be considered.  
We evaluated to what extent exome sequencing in combination with linkage analysis allowed us 
to identify the causative genes in such small families with unknown cause.  
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CHAPTER 2  
RESEARCH OBJECTIVES 
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OBJECTIVES OF THE RESEARCH 
The general objective is to contribute to understanding the genetics of congenital heart defects 
(CHD) and congenital cardiomyopathies. 
To this aim, we propose to 
1. evaluate the use of Next Generation Sequencing (NGS) in the detection of causal mutations 
of syndromic CHD in sporadic and familial cases. 
 
2. identify and characterize novel genes in individuals and families. 
Based on our findings and current literature, to provide updated guidance for the introduction 
of NGS into the congenital cardiology clinic. 
  
33 
 
 
 
 
                                                                     
CHAPTER 3 
THE USE OF NEXT GENERATION SEQUENCING (NGS) IN THE 
DETECTION OF CAUSAL MUTATIONS OF SYNDROMIC CHD IN 
SPORADIC CASES 
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INTRODUCTION 
Congenital heart defects (CHD) , including trivial lesions such as small muscular ventricle septal 
defects, have an incidence of 7,5/100 live births making it the most common birth defect [1]. Of 
these, 22% have a sporadic CHD in the context of a broader syndrome, i.e. the presence of 
additional major malformations and or dysmorphism [2-4]. This is associated with an increased 
morbidity and mortality and carries a high risk of developmental delay and intellectual disability. 
Thus, syndromic CHD has an important impact on the individual, his family and on society. There 
is an indispensable need for etiological diagnosis, since it is in this group that genetic counselling 
is frequently requested with regard to recurrence risks. In addition, a diagnosis may aid in 
establishing the prognosis with regard to intellectual disability (ID) and additional medical 
complications which are often not yet visible in new-borns. 
Identifying the underlying genetic defect in these cases still presents a major challenge due to the 
vast etiological heterogeneity of syndromic CHD. Not only can different genes be involved, but 
also different types of mutations (chromosomal or at the gene level) and different inheritance 
patterns exist [5, 6]. Using a clinical approach, an exact etiological diagnosis can be reached in 
about 55% of cases, which have a clinically recognisable syndrome [4]. The diagnosis is 
straightforward for common syndromes (e.g. Down syndrome and 22q11.2 microdeletion 
syndrome), or for those with a characteristic pattern of malformations (e.g. septal defects and 
pre-axial hand defects in Holt-Oram syndrome) or with a highly characteristic type of CHD (e.g. 
supravalvular aortic stenosis in Williams syndrome). The suspected diagnosis can then be 
confirmed by a targeted genetics test, e.g. FISH, array-CGH or gene sequencing. However, 
reaching a clinical diagnosis can be challenging is certain circumstances. Special expertise is 
required to establish a diagnosis in the large number of rare disorders that feature a CHD (e.g. 
Kabuki syndrome), especially when manifestations can be variable (e.g. Alagille syndrome or 
Noonan syndrome). Additionally, in the prenatal or early neonatal setting, the full clinical 
phenotype is not yet apparent, further complicating clinical diagnostics. 
In cases where no clinical diagnosis can be reached, genetic testing has an important role. 
Genome-wide screening for the presence of mutations is therefore an important next step after 
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clinical evaluation. Since the early 2000’s, microarray-CGH was introduced as a tool to screen for 
small chromosomal imbalances. On average, this has led to a diagnosis in 15-20%, based on the 
inclusion criteria and expertise of clinical pre-screening [7]. More recently, massive parallel 
sequencing allowed genome-wide screening of all genes for the presence of sequence alterations.  
 
Previous genetic studies of individuals with a clinically unexplained developmental disorder have 
shown that de novo (dominant) mutations play a major causative role [8-10]. Most syndromic 
CHDs are also caused by de novo dominant mutations, whereas recessive or X-linked inheritance 
is rare, at least in a society where consanguinity is exceptional [11-13]. We here evaluated, in a 
pilot study, exome sequencing as a tool to identify the causal mutations in syndromic non-familial 
CHD. By selecting sporadic cases with a severe and syndromic phenotype, we expected that they 
are enriched for a de novo genetic origin [7, 14]. The most efficient way to identify such de novo 
mutations is a trio approach, where the whole exome sequence (WES) of both parents and the 
affected child are compared. Due to the current high cost of WES analysis in a trio setting, we 
compared this to an index-only approach. Finally, we participated in an international 
collaboration to study a large cohort of syndromic and non-syndromic CHD patients in a trio 
setting.  
 
PATIENTS AND METHODS 
Patient selection and description 
Since it is known that the majority of severe sporadic syndromes have a de novo autosomal 
dominant cause, we hypothesized that also in those with an unknown cause, a de novo dominant 
mutation is present in a significant proportion. For this reason, we analysed nine trios, consisting 
of both parents and the affected child. In addition, we analysed four index-only cases to compare 
both approaches.  
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Inclusion criteria 
1. Syndromic CHD with syndromic defined as the presence of 1 additional major abnormality 
apart from the CHD, or intellectual disability not otherwise explained and/or dysmorphism, 
defined as 3 or more minor anomalies. 
2. An unknown cause of the syndrome after extensive evaluation: 
* All patients were examined by an experienced clinical geneticist and clinical pictures were 
available for discussion with other clinical geneticists and for review of the phenotype in case a 
mutation was found. Clinical information on the parents were available.  
* The patients were old enough to be clinically (re-)evaluated with regard to psychomotor 
development i.e. > 12 months. 
* High resolution array-CGH was normal in the patient and showed no unclassified variants. 
3. DNA was available from the patient and both parents in trio analysis.  
4. Sporadic patients: no familial occurrence i.e. no other family members with the same or a 
similar condition; no familial occurrence of a CHD in a first or second degree relatives. This was to 
exclude the possibility that the heart defect and additional features have a separate cause. 
5. No external causes identified: no teratogens during pregnancy, no neurological damage (e.g. 
during surgery). 
The study was approved by the Ethical Committee University Hospital Leuven (S52853 – 
B322201010111). Informed consent was obtained from all parents.  
The clinical data are presented in Table 1. 
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 TABLE 1 
Clinical description of cases  
Patient 
Gender 
Gene 
Age 
ID
 
HC 
W
eight 
Height 
CHD 
O
ther m
ajor 
m
alform
ations 
M
inor m
alform
ations 
O
ther characteristics 
1 
M
 
DYRK1A 
4,23 
S 
-5 
-3,3 
-2,8 
CoA, HAA,  
a. lusoria 
m
icrocephaly, sm
all 
cerebellum
 pachygyria, 
sparse hair, deep-set eyes, 
sm
all scrotum
, sim
ple ears 
hypertonia, epilepsy, 
IgG2-deficiency 
2 
F 
M
EIS2 
4,00 
M
 
0,1 
-0,6 
-1,3 
ASD II, VSD, 
CoA 
cleft palate; congenital 
lobar em
physem
a, 
achalasia 
bitem
poral narrow
ing, 
broad 1st ray, gap toe 1-2,  
syndactyly toe II-III 
severe feeding 
problem
s, GERD, 
autism
 
3 
F 
SALL1 
9,69 
M
 
-2,7 
-2,8 
-1,4 
ToF 
m
icrocephaly, 
congenital renal 
hypoplasia 
facial dysm
orphism
, 
excessive pubic fat, deep 
palm
ar grooves, long 
slender fingers, short 5
th 
toe 
severe feeding 
problem
s, dry skin 
4 
F 
EFTUD2 
35,77 
S 
-3,1 
-1,8 
-0,9 
Truncus 
arteriosus 
m
icrocephaly, cleft 
palate, hearing 
im
pairm
ent 
facial dysm
orphism
 
epilepsy 
5 
M
 
 
4,6 
S 
-0,4 
-1,6 
-1,9 
AVSD 
unilateral renal 
agenesis,  hypospadias, 
cryptorchidism
 
facial dysm
orphism
, 
branchial appendage, 
presacral dim
ple, shaw
l 
scrotum
, short preputium
 
 
6 
M
 
 
4,95 
N
L 
-0,1 
-3 
-4,4 
ToF 
esophageal atresia, 
m
icrocolon, 
om
phalocele, pyloric 
hypertrophy, 
subependym
al cyst 
facial dysm
orphism
, 
clinodactyly finger 2 &
 5  
hypoplasia of term
inal 
phalanges, syndactyly toes 
II-III, sacral hairy dim
ple 
fine m
otor and social 
developm
ent norm
al, 
gross m
otor and 
verbal developm
ental 
delay 
7 
M
 
 
15,98 
S 
-1,9 
-0,5 
-0,2 
AP w
indow
, 
IAA 
Hirschsprung's disease, 
m
icrocephaly 
none 
 
8 
F 
 
8,21 
M
 
-0,9 
-3,1 
-2,9 
AVSD 
agenesis corpus 
callosum
, bilateral focal 
cataract, unilateral 
dilated pyelon 
facial dysm
orphism
, 
posterior rotated ears, 
transverse palm
ar grooves, 
pedal edem
a 
 
9 
M
 
 
18,46 
M
 
N
A 
-0,3 
0,9 
ToF 
kyphosis and scoliosis 
   
facial dysm
orphism
, high 
palate, w
ebbed neck, 
slender fingers and hands, 
diffuse striae,  tight 
ham
strings 
pes planus, bilateral 
hallux valgus, pectus 
carinatum
, strabism
us 
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 Patient 
Gender 
Gene 
Age 
ID
 
HC 
W
eight 
Height 
CHD 
O
ther m
ajor 
m
alform
ations 
M
inor m
alform
ations 
O
ther characteristics 
10 
M
 
AN
KRD11 
13,61 
M
i 
-2,2 
-4,8 
-3,8 
ASD II, VSD 
hearing loss 
facial dysm
orphism
 
autism
, m
icrocephaly 
11 
F 
 
4,52 
N
L 
0,2 
0,4 
0,1 
Right 
isom
erism
, 
U
VH, AVSD 
none 
ectopic thyroid, congenital 
hypothyroidism
 
 
12 
F 
 
19,07 
N
L 
N
A 
-1,6 
-0,3 
PDA, CoA, 
PAPVR 
renal hypoplasia, cleft lip 
and palate 
facial dysm
orphism
 
GH deficiency, 
cholestatic liver 
disease, retinopathy 
13 
F 
 
15,2 
S 
-5,3 
-7,28 
-9,0 
PDA 
m
icrocephaly 
facial dysm
orphism
 
feeding problem
s 
 Cases 1-9 w
ere analysed by m
eans of trio W
ES, cases 10-14 by index-only W
ES. Colum
ns show
 gender, Gene involved in the phenotype, age at 
exam
ination, level of intellectual disability, biom
etric values, type of CHD, description of other m
ajor m
alform
ations, description of m
inor 
m
alform
ations and other characteristics. Level of intellectual disability is classified into norm
al (N
L), m
ild (M
i), m
oderate (M
) and severe (S). 
Congenital Heart Defects are described as coarctation of the Aorta (CoA), Hypoplastic aortic arch (HAA), atrial septal defect type secundum
 (ASD II), 
ventricle septal defect (VSD), tetralogy of Fallot (ToF), atrioventricular septal defect (AVSD), aortopulm
onary w
indow
 (AP w
indow
), interrupted aortic 
arch (IAA), univentricular heart (U
VH), patent ductus arteriosus (PDA) and partial anom
alous pulm
onary venous return (PAPVU
). Head Circum
ference 
(HC), w
eight and height is given as standard deviations. Som
e data w
ere not available (N
A). 
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Exome sequencing 
Trio analysis 
WES was done by the Genomics Core KU Leuven/UZ Leuven as follows: Library construction for 
all samples were prepared using TruSeq DNA Library Preparation Kit (Illumina, Inc., San Diego, CA, 
USA) in which platform-specific adaptors and unique DNA indexes were ligated. For each sample, 
1 µg genomic DNA was sheared by sonication to approximately 300bp fragments, followed by 
end-repair, adenylation and adapter ligation steps. DNA sequencing libraries were subsequently 
enriched with the SeqCap EZ Human Exome Library v3.0 (Roche, NimbleGen), reads were 
generated on the Illumina HiSeq2000 or HiSeq2500 machine using a paired-end 2x100 bps 
protocol with 3-4 exome-seq samples pooled per lane of a sequencing flow-cell. Sheared DNA, 
whole genome libraries and enriched exome-seq libraries were validated using DNA-1000 chips 
on the BioAnalyser (Agilent), and library concentrations were determined using the dsDNA Broad 
Range Assay using the Qubit (Invitrogen). Post-capture LM-PCR amplification was performed 
using the Library Amplification Readymix containing KAPA HiFi DNA Polymerase with 14 cycles of 
amplification. 
Sequence reads were aligned to the human genome reference sequence (Genome Assembly 
GRCh37/hg19) with the Burrows-Wheeler Aligner (BWA v. 0.6.2 or v. 0.7.8). SAMtools (v. 0.1.18 
or v. 0.1.19) were used for SAM to BAM files conversion, sorting and indexing alignments. Picard 
tools (v. 1.78 or v. 1.118) were used to compute quality metrics and mark PCR-generated 
duplicates. The Genome Analysis Toolkit (GATK v. 2.4.9 or v. 3.2.2) software package was used to 
perform local realignment around indels and base quality score recalibration. SNPs and small 
indels were called using GATK HaplotypeCaller (v. 2.4.9 or v.3.2.2). Variants annotation was 
performed with ANNOVAR (v. 11-0882013 or v. 11-02-2013), including data sets from dbSNP137, 
the NHLBI 6500 Exome and 1000 Genomes projects for variant frequencies, amino acid change, 
functional predictions from SIFT, Polyphen2, LRT, MutationTaster and PhyloP. 
The total target region was 63 mega base pairs (Mb).  Quality assurance was aimed at having 20X 
coverage in 80% of the targeted exome bases. 
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Index-only analysis 
Due to the cost of WES in Trio analysis, we collaborated with the Human Genome Sequencing 
Center (HGSC) at Baylor College of Medicine through the Baylor-Hopkins Center for Mendelian 
Genomics initiative in an index-only analysis. Whole exome sequencing was performed at the 
HGSC as described previously [15]. Libraries were constructed into Illumina paired-end pre-
capture libraries according to the manufacturer’s protocol (Illumina 
Multiplexing_SamplePrep_Guide_1005361_D) with modifications as described in the BCM-HGSC 
protocol (https://www.hgsc.bcm.edu/content/protocols-sequencing-library-construction). For 
each sample, 0.5 µg of genomic DNA was sheared by sonication to 200-300bp fragments, followed 
by end-repair, adenylation and adapter ligation steps. DNA sequencing libraries were 
subsequently enriched with the SeqCap EZ Human Exome Library v3.0 (Roche, NimbleGen), and 
paired-end reads were generated on the Illumina HiSeq2000 platform with 6 samples pooled per 
lane of a sequencing flow-cell. After the final AMPure XP bead purification, quantity and size of 
the capture library was analyzed using the LabChip GX electrophoresis system. Post-capture LM-
PCR amplification was performed using the Library Amplification Readymix containing KAPA HiFi 
DNA Polymerase with 12 cycles of amplification. The total target region was 37 Mb. The samples 
achieved 89% of the targeted exome bases covered to a depth of 20X or greater. Initial sequence 
analysis was performed using the HGSC Mercury analysis pipeline [16, 17] 
(https://www.hgsc.bcm.edu/software/mercury) which moves data through various analysis tools 
from the initial sequence generation on the instrument to annotated variant calls (SNPs and intra-
read insertions/deletions). Next, the Atlas2 suite (Atlas-SNP and Atlas-indel) was used to call 
variants and produce a variant call file (VCF). Finally, annotation data was added to the VCF using 
a suite of annotation tools “Cassandra” that brings together frequency, function, and other 
relevant information using AnnoVar with UCSC and RefSeq gene models, as well as other internal 
and external data resources. 
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Variant filtering 
1. Trio analysis 
Exome sequences were obtained from both parents and the patient. VCF files were converted 
into Excel files and all further filtering was done manually. Initially, when developing the filtering 
process, we compared different annotation tools (Cassava and GATK), different genome browsers 
(RefGene, Ensembl and knownGene), various chronological orders of filtering steps and stringent 
versus less stringent filtering. We analyzed variants with two classes of quality. Class 1 calls, the 
best quality calls, were all calls (reference or mutant) emitted with a genotype quality bigger than 
70. The genotype quality is the smallest non-zero phred likelihood (PL), with the zero PL value 
being the genotype given to the call. The PL values were always given in the following order: 
homozygous reference, heterozygous, homozygous variant. Class 1 calls were thus calls for which 
both non-zero PL values were bigger than 70, e.g. a homozygous variant has a PL = 185,96,0. Class 
2 calls were less confident calls for which one non-zero PL value is bigger than 70, e.g. a 
heterozygous variant has a PL = 185,0,45. Class 3 calls were not analyzed as these calls were calls 
for which both non-zero PL values were smaller than 70, and thus were classified as “no call”. 
 
1.1. De novo dominant or X-linked hypothesis 
To exclude local rare variants, we first filtered all variants in the patient against variants in 72 
other in-house exomes from patients with various other, distinct phenotypes. All heterozygous 
variants occurring in one other patient were excluded. Next, we filtered for variants that were 
reference in the parents and mutant in the patient, thus retaining possible de novo variants. We 
then retained exonic nonsynonymous variants, exonic/splicing and intronic splicing variants (< 5 
positions from the splicing site). Next, we only retained variants with a frequency of <1%, or with 
an unknown frequency, in the 1000 Genomes Project. In-silico predictions by Polyphen, Mutation 
Taster and SIFT were used as an additional filter when necessary. Only variants predicted as 
damaging or disease causing by 2 or more in-silico tools were then further analysed. The 
remaining list was manually curated with literature using UCSC, OMIM, Pubmed and GeneCards. 
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1.2. Autosomal recessive inheritance   
1.2.1. Homozygous inheritance 
Firstly, the patient was filtered against 72 other in-house exomes, excluding any variant for which 
another patient was homozygous. Next, we retained only variants for which the parents were 
heterozygous. Only exonic, exonic/splicing and potential splicing variants were retained. Only 
variants occurring with a frequency of <5% or with an unknown frequency in the 1000 Genomes 
Project were included. Remaining variants were manually filtered according to inheritance 
pattern: both parents needed to be heterozygote. In-silico predictions and manual curation of the 
remaining variants were then done as described above.   
1.2.2. Compound heterozygous inheritance 
Firstly, the patient was filtered against 72 other in-house exomes, excluding any variant for which 
an individual was homozygous. Next, we retained only variants for which the parents were 
heterozygous. Only exonic, exonic/splicing and splicing variants were included as described 
previously. Variants occurring with a frequency of <5% or with an unknown frequency in the 1000 
Genomes Project were included. Remaining variants were manually filtered according to the rule: 
one paternal and one maternal inherited variant occurring in the same gene. In-silico predictions 
and manual curation of the remaining variants were done as described above.  
 
1.3. X-linked recessive inheritance 
Only variants on the X-chromosome were selected in the patient, and reference calls were 
excluded. Only maternal inherited variants were included as the father would have to be affected 
if he was carrying the variant. Only exonic, exonic/splicing and splicing as described above were 
included. Variants occurring with a frequency of <5% or with an unknown frequency in the 1000 
Genomes Project were included. In-silico predictions and manual curation of the remaining 
variants were done as described above. 
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2. Index-only analysis 
To identify autosomal dominant or X-linked candidate mutations, the patient was first filtered 
against 79 local exomes, i.e. where only the patient is heterozygous for a specific variant. Only 
exonic, exonic/splicing and splicing as described above were included. Variants occurring with a 
frequency of <1% or with an unknown frequency in the 1000 Genomes Project were included. In-
silico predictions by Polyphen, Mutation Taster and SIFT were used with discretion as an 
additional filter; only variants predicted as damaging or disease causing by 2 or more in-silico 
tools were further analyzed.  The remaining variant list was then manually curated with literature 
using UCSC, OMIM, Pubmed and GeneCards.  
For the autosomal recessive hypothesis, homozygous calls were kept in the patient where no 
other patient was homozygous. Heterozygous filtering was also done by keeping all heterozygous 
calls and only retaining the genes where two variants occurred in the same gene. Further filtering 
was not possible for compound heterozygosity (one maternal and one paternal variant in the 
same gene) as parental WES data was not available.  
 
RESULTS 
The variants filtering in the different approaches is schematically shown in figure 1 and 2. 
44 
 
Figure 1 
Variant filtering steps for de novo inheritance using trio analysis w
ith the rem
aining variants after each filtering step show
n in the accom
panying table.  
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Figure 2 
Variant filtering steps for dom
inant or X-linked inheritance using index-only analysis w
ith the rem
aining variants after each filtering step show
n in the 
accom
panying table. 
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Identification of pathogenic mutations 
Trio-analysis 
We analysed 9 patients with a syndromic CHD by using a trio approach. A pathogenic mutation 
was identified in 4 of them, 3 in known genes and one in MEIS2 [18] which had previously 
been suggested as a candidate gene for CHD, ID and cleft palate. Below, we describe clinical 
and genetic data in these four cases in more detail.   
Patient 1 (DYRK1A) 
This boy was the only child of healthy, unrelated, Caucasian parents. During pregnancy, intra-
uterine growth retardation (IUGR) was noted at 34 weeks. He was delivered by caesarean 
section because of transverse position, at a gestational age of 38 weeks. Weight at birth was 
2,7 kg (SD -1,2), length 46 cm (SD -1,64) and head circumference 32,7 cm (SD -1,64). On day 8 
he was diagnosed with necrotizing enterocolitis, necessitating abdominal surgery and 
resulting in short bowel. Due to persistent feeding problems, nasogastric feeding was 
necessary in infancy. Cardiac evaluation on day 6 showed a bicuspid aortic valve with 
borderline left ventricle and mitral valve as well as an important preductal coarctation of the 
aorta. There was a right arteria lusoria.  The coarctation was initially treated with 
percutaneous stenting, at the age of 5 months a coarctectomy was performed. He was 
hypertonic and had hyperreflexia. MRI at the age of 1 month showed enlarged, symmetrical 
sulci, cisterns and ventricles with global hypoplasia of the cerebellum - most prominent in the 
parietal region. Hypoplasia of the corpus callosum was also noted. 
Ophthalmologic evaluation revealed small and pale optic discs.  At the age of 3 years he was 
diagnosed with epilepsy. His development was severely delayed, and he followed special 
education.  Facial features included decreased facial expression, sparse hair and deep-set 
eyes, prominent nasal bridge, bitemporal narrowing, protrusion of the upper lip and mild 
retrognathia (Figure 3). He had a small scrotum, widely spaced nipples and pectus excavatum.  
At the age of 6 years 7 months, weight was 16,3 kg (SD -2,8), height 110 cm (SD -2,2) and head 
circumference 44,5cm (SD -4,7).   
 
After variant filtering as outlined in the methods section, we identified 77 remaining variants. 
This gene list was manually curated using functional data and genotype-phenotype 
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correlations for the implicated genes. We thus identified a de novo stopgain mutation in the 
DYRK1A-gene resulting in a premature stopcodon NM_001396.3 c.C1309T:p.R437X. Results 
were confirmed by Sanger sequencing. 
 
 
Figure 3 
Clinical pictures of the patient with a de novo DYRK1A loss-of-function mutation at age 3 years 
7 months.  He has decreased facial expression, sparse hair, deep-set eyes, prominent nasal 
bridge, bitemporal narrowing, protrusion of the upper lip and mild retrognathia. He has widely 
spaced nipples and pectus excavatum. 
 
Patient 2 (MEIS2) 
This female patient presented with multiple congenital malformations including cleft palate 
and a CHD (septal defects and aortic coarctation). She had severe feeding problems, severely 
delayed gross motor and verbal development. She was diagnosed with moderate ID and 
autism spectrum disorder. Facial dysmorphism consisted of bitemporal narrowing, arched and 
laterally extended eyebrows, mild upslanting palpebral fissures, deep set eyes, a tented upper 
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lip, thin upper vermilion, full lower vermilion, broad first ray of hands and feet, a gap between 
the first and second toes and syndactyly of toe II-III. 
After variant filtering we identified variants in 48 candidate genes. This list was manually 
curated using functional data and genotype-phenotype correlations for the implicated genes. 
We thus identified a de novo non-frameshift deletion of three base pairs in the MEIS2 gene 
NM_170674.2 c.998_1000del:p.Arg333del as the most likely cause. This caused a deletion of 
three nucleotides GAA and thus led to deletion of the amino acid Arginine (Arg). Results were 
confirmed by Sanger sequencing. 
Since this was the first case with an intragenic sequence alteration, we reported this in a 
separate manuscript (see annex Chapter 3.1 [18]). 
 
Patient 3 (SALL1) 
This female patient was an only child of unrelated parents. No other family members were 
known with intellectual disability, congenital heart defects or renal abnormalities. She had 
IUGR with a birth weight of 1,4 kg (SD -4,2) at the PMA of 38 weeks. She was diagnosed with 
Tetralogy of Fallot with agenesis of the pulmonary valve and an aneurysmatic pulmonary 
artery as well as trifurcation of the brachiocephalic truncus for which she underwent surgical 
correction. She had congenital renal hypoplasia with chronic renal insufficiency. At the age of 
9 years her head circumference was 48cm (SD -2.7), her weight 20.2kg (SD -2.8) and her height 
127.3 cm (SD -1.4), and she had moderate ID. There was facial dysmorphism with an 
asymmetric crying face, dry skin, deep palmar grooves, long slender fingers, excessive pubic 
adipose tissue, a short fifth toe and a relatively long first toe.  
After variant filtering as outlined in the methods section, we identified 97 remaining variants. 
This gene list was manually curated using functional data and genotype-phenotype 
correlations for the implicated genes. We thus identified a de novo frameshift mutation in the 
SALL1-gene c.1998_1999del:p.666_667del. Results were confirmed by Sanger sequencing. 
Patient 4 (EFTUD2) 
This was a female patient with a truncus arteriosus and right aortic arch. The diagnosis was 
made late in childhood when there was already irreversible obstructive pulmonary 
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hypertension and Eisenmenger syndrome as well as moderate truncal valve insufficiency 
grade 2-3/4.  She had severe intellectual disability.  There was microcephaly with a head 
circumference of 47 cm (SD -3,1) at the age of 8 years and 5 months. Her weight and height 
were normal. She had a cleft palate, hearing impairment, epilepsy which started in infancy. 
She had facial dysmorphism with micrognathia and upslant of the eyes. 
After variant filtering, we identified 83 remaining variants. This gene list was manually curated 
using functional data and genotype-phenotype correlations for the implicated genes. We thus 
identified a de novo frameshift mutation of one base pair in the EFTUD2-gene 
NM_004247:exon9:c.671delG:p.G224fs. Results were confirmed by Sanger sequencing. 
 
Unsolved Trios 
In the unsolved trios the same filtering methods were used as mentioned before and resulted 
in between 22 and 109 variants in de novo calls. In the hypothesis of autosomal recessive 
inheritance between 4 and 26 variants were left. 
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Index-only analysis 
Of the four cases studied, a pathogenic mutation could be identified in one. The detailed 
clinical description and genetic data are given below.  
 
Patient 10 (ANKRD11) 
The boy was the only child of unrelated parents. No other family members were known with 
developmental delay or intellectual disability. He was born at term with a birth weight of 3000 
gram. He was edematous. The diagnosis of a congenital cardiopathy was made; i.e. an ASD II 
and VSD. No cardiac interventions or surgery was necessary. He had a nasal speech and was 
hearing impaired. He had microcephaly with a head circumference of 48,9cm (SD -2.2), weight 
15,7kg (SD-4.8) and height 109cm (SD -3.8) at the age of 8 years. He received growth hormone 
therapy for his short stature. He had mild intellectual disability and followed special education 
for children with special needs and autism spectrum disorder.  He had camptodactyly of 
several fingers with a broad first ray and bilateral short fourth metatarsal. The space between 
the first and second toe was increased. His maxillary incisors were broad. There was 
endorotation of the femur and mild bowing of the lower legs. He had a rigid back with normal 
curvature. Previous genetic testing, including microarray-CGH and mutation analysis of 
HDAC4-gene were normal. After variant filtering, 308 variants were left. Further manual 
curation showed a nonsense mutation in the ANKRD11 gene (c.7189C>T, p.Gln2397*). This 
mutation occurred de novo, and confirmed the diagnosis of KBG syndrome [19]. 
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DISCUSSION 
The introduction of NGS has revolutionized the identification of gene mutations. However, the 
bottleneck has shifted from variant identification to variant interpretation. In this study, we 
have applied whole exome sequencing to identify causative mutations in individuals with a 
sporadic, syndromic CHD.  
A de novo filter in a trio approach resulted in finding a genetic etiology in 4 out of 9 cases. In 
the index-only analysis, a causal mutation was identified in only one case out of 4. Whereas 
the figures in this pilot study were small we found, not unexpectedly, that filtering for de novo 
mutations using a trio approach increased efficiency in filtering. However, even in a trio 
analysis, on average still 65 candidate variants remained (range 22-109), compared to an 
average of 259 (range 51-339) in the index-only analysis. This was partly due to the initial 
poorer quality of the sequencing at the start of this project. At the initial phase of exome 
introduction in our laboratory with the first variant calling algorithm, calling was less reliable 
and thus we also included the less reliable calls, resulting in an inflation of the number of 
remaining potentially de novo variants. Currently, with improved sequencing quality and 
bioinformatics filtering tools, a much lower number of de novo variants is expected after 
filtering.  
In a diagnostic setting, additional filtering could be done using a panel of known genes 
associated to the phenotype under study. One approach is targeted capture and resequencing 
of a panel of known CHD genes or of all known genes associated to a genetic disorder 
(Mendeliome). The coverage is greatly improved with this method and the frequency of 
variants with unknown significance is reduced. The drawback is that no new genes will be 
discovered to broaden the genetic landscape of unsolved syndromic cardiopathies. 
Establishing a genotype-based filter will require an exhaustive list of gene-phenotype 
associations. However, for CHD, such a gene list is almost certainly incomplete. First, CHD is a 
feature of many syndromes, and in some, CHD only rarely occurs. In a recent study, syndromic 
CHD patients were found to carry an excess of de novo protein truncating variants in 
Developmental disorder (DD) genes not known to be associated to CHD [20]. In our study, we 
identified the first DYRK1A mutation associated to a CHD, but since then, DYRK1A has been 
found to be an important ID gene, associated to CHD in a significant proportion of cases [20, 
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21]. Since all cases we studied were known with ID, we could use a filter for all known genes 
associated with ID. This list of ID-genes is extensive [10], and still incomplete, since novel genes 
for ID are being identified continuously. This was illustrated by our finding of a MEIS2 mutation 
in one of the cases [18] where it has been a candidate gene for developmental disorders, but 
no prior intragenic sequence variants have been described. Additionally, it would be difficult 
to use in a neonatal setting as ID only becomes apparent at a later age. 
An additional requirement for optimal functioning of such a phenotype-based filtering is a 
correct phenotypic description. Standardized nomenclature exists, for instance the Human 
Phenotype Ontology (HPO) [22], which is being adopted as the standard in the field of 
developmental disorders. Whereas the standardized description of major malformations (e.g. 
CHD, cleft lip, polydactyly etc.) is reliable, the description of dysmorphism is much more 
challenging. Dysmorphism is the combination of several minor anomalies, and a standardized 
nomenclature for minor anomalies exists [23]. However, many features remain subjective 
(e.g. deep set eyes, prominent nasal bridge, bitemporal narrowing). HPO terms to classify 
patients according to phenotypic similarities have been successfully used in computational 
methods [24].  In this computational study variants in the 2741 established Mendelian disease 
genes were grouped in a disease-associated genome (DAG) to develop a targeted enrichment 
panel (7.1 Mb) which had a high coverage of more than 20X in 98%. Data generated was 
analyzed by a computational method called Phenotypic Interpretation of eXomes (PhenIX) 
that evaluated and ranked variants based on their predicted pathogenicity (pathogenicity 
score defined as the single most pathogenic according to three in-silico tools) and semantic 
similarity of the patient phenotype to known Mendelian diseases. A variant score was 
calculated (Variant score = population frequency x pathogenicity score) and genes were 
ranked accordingly. The causal gene was ranked in the first place in computer simulations in 
86% of the time and this tool enabled genetic diagnosis in 28% of unknown cases (n= 11) in a 
prospective study.  
A promising future development is the use of automated recognition of facial features or facial 
gestalt on 2D pictures of a patient, instead of a (subjective) clinical description [25].  
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We anticipate that improved bioinformatics and the inclusion of standardized phenotypic 
information will greatly improve the currently slow and labour-intensive process of variant 
filtering in diagnostic whole exome sequencing.  
After initiating this study, we had the opportunity to participate in a large multicenter study, 
which was led by the Wellcome Trust Sanger Institute in Hinxton UK, with the aim to study the 
genetics of CHD using WES, in 610 syndromic and 1281 non-syndromic patients [20]. We 
contributed 60 trios and 30 singletons.  In this study, de novo mutations (DNM) and rare 
inherited variants were compared to a null mutation model in genes from 3 groups: autosomal 
dominant (AD) CHD genes, AD-developmental disorder (DD) associated genes and all 
remaining protein-coding genes. One of the main conclusions was a larger excess of de novo 
mutations with functional effects (protein truncating (PTV) or missense) in syndromic (S-CHD) 
compared to non-syndromic (NS) CHD cases (Table 2). This confirms the previous observation 
by Homsy et al [26] who reported an excess of de novo PTV in S-CHD (20% of cases) compared 
to only 2% in NS-CHD cases. Of interest, when the genes implicated were stratified according 
to their known gene-phenotype associations, a significant excess of PTV and missense was 
also detected in genes not previously associated with CDH, known DD-genes but also in the 
remaining genes. This confirms that the current genotype-phenotype associations are 
incomplete, and that many CHD genes still remain to be identified. Several novel CHD genes 
were also reported, and the results of our small study indicate that the MEIS2 gene can be 
added to this list.  
In conclusion, our study shows that trio exome analysis is an efficient way to identify 
pathogenic mutations in sporadic cases with a syndromic CHD. The diagnostic yield is high, 
which has a clear benefit to the patient and his family. Moreover, novel genotype-phenotype 
correlations emerge, and new genes involved in CHD can thus be identified.    
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Type of de novo 
mutation 
Gene 
set 
S-CHD 
(n=518) Excess P-value 
NS-CHD 
(n=847) Excess P-value 
 
CHD 27 80,56 1,21x10-43 4 7,3 2,62x10-04 
Protein Truncating DD 12 18,36 3,49x10-13 1 0,94 NS 
 
All 67 1,75 8,92x10-06 67 1,07 NS 
 
CHD 22 8,64 7,35x10-15 12 2,88 3,97x10-04 
Missense DD 14 2,75 2,68x10-04 11 1,32 NS 
 
All 371 1,34 2,85x10-08 593 1,31 1,15x10-10 
 
Table 2 Excess of DNMs in S-CHD and NS-CHD showing the types of DNMs with their functional 
consequences leading to either a protein truncating or missense mutation. Gene sets of congenital heart 
defects (CHD), developmental disorders (DD) and all remaining protein coding genes were compared. 
Adapted from Sifrim et al, Nature Genetics 2016 Sep [20]. 
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CHAPTER 3.1 
MEIS2 Involvement in Cardiac Development, Cleft Palate and 
Intellectual Disability 
 
 
 
 
 
 
 
 
 
Jacoba J. Louw, Anniek Corveleyn, Yaojuan Jia, Greet Hens, Marc Gewillig, Koenraad Devriendt 
Adapted from: American Journal of Medical Genetics May 2015; 167A (5). 
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ABSTRACT 
MEIS2 has been associated with cleft palate and cardiac septal defects as well as varying degrees 
of intellectual disability. We present a female patient with a more severe phenotype compared to 
previous reported patients. She has multiple congenital malformations; cleft palate and congenital 
heart defect characterized by septal defects and aortic coarctation. She has severe feeding 
problems, facial dysmorphism, severely delayed gross motor and verbal development and autism 
spectrum disorder. Facial dysmorphism consisting of bitemporal narrowing, arched and laterally 
extended eyebrows, mild upslanting palpebral fissures, deep set eyes, a tented upper lip, thin 
upper vermilion, full lower vermilion, broad first ray of hands and feet, a gap between the first and 
second toes and syndactyly of toe II-III. 
Exome sequencing revealed a non-frameshift deletion (c.998_1000del:p.Arg333del) of three base 
pairs in the MEIS2 homeodomain. The more severe phenotype is most probably due to dominant-
negative mechanisms. This is the first report showing a de novo small intragenic mutation in MEIS2 
and further confirms the important role of this gene in normal development. 
 
KEYWORDS 
MEIS2, cleft palate, cleft lip, cardiopathy, heart, intellectual disability, next generation sequencing 
(NGS) 
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INTRODUCTION 
MEIS2 is a homeodomain-containing transcription factor of the TALE superfamily. Cytogenetic 
studies have identified MEIS2 as a candidate gene for congenital malformations of the heart and 
palate. In 2007, a first patient with atrial septal defect type secundum (ASD II), cleft palate, 
moderate mental delay, severe speech delay and mild motor delay was described with a 5.3Mb 
deletion in 15q14 [Erdogan et al., 2007]. This was followed by two more patients with cleft palate 
and ventricle septal defect (VSD), respectively showing a deletion of 5.6Mb and 123kb in 15q14 
[Chen et al., 2008; Crowley et al., 2010]. MEIS2 was the only gene overlapping in all of these 
patients, making it the primary candidate gene for cleft palate, cardiac septal defects and varying 
degrees of developmental delay. More recently, nine patients, including a family with four 
patients, demonstrate that MEIS2 disruption alone can cause cleft palate and cardiac defects (VSD) 
[Chen et al., 2008; Johansson et al., 2014; Crowley et al., 2010]. One of these also suffered from 
autism spectrum disorder, albeit with mild intellectual disability (ID) and without cleft palate or 
cardiopathy [Johansson et al., 2014]. Interestingly, most of these patients had delayed motor 
development, but varying degrees of mental disability, ranging from normal to moderate ID. It 
remains uncertain whether the ID observed in the other individuals is related to a deletion of 
nearby genes, or related to haploinsufficiency of the MEIS2 gene. We here report the first patient 
with an intragenic MEIS2 mutation detected by exome sequencing. 
 
CLINICAL REPORT 
A female patient is the second child of healthy, unrelated parents, and family history is negative 
regarding congenital malformations. She was born at term after an uneventful pregnancy, with 
weight 3650gram (25-50th centile), length 51cm (50th centile) and head circumference 36cm (50-
75th centile). Multiple congenital malformations were present, a cleft of the soft and posterior part 
of the hard palate,  a congenital heart defect (a large perimembranous, inlet-to-outlet VSD, an ASD 
II, a small left ventricular outflow tract without obstruction, and aortic coarctation). Surgical 
correction with coarctectomy and VSD closure was done. She also had congenital lobar 
emphysema of the left upper lobe for which a lobectomy was performed at the age of 1 month. 
There were severe feeding problems with gastro-esophageal reflux, oral aversion, aerophagia and 
achalasia necessitating gastrostomy and Botox infiltrations. She has arched and laterally extended 
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eyebrows, mild upslanting palpebral fissures, deep set eyes, a tented upper lip, thin upper 
vermilion, full lower vermilion. There was bitemporal narrowing. She had a broad first ray of hands 
and feet, a gap between the first and second toes and syndactyly of toe II-III (Figure 1). Biometry 
at the age of 5years 8months was height 108.5cm (10th centile) and weight 15.8kg (3rd centile). 
Her gross motor and verbal development was severely delayed. She could sit at the age of 17 
months and walk at the age of 30 months. At the age of 4 years she pronounces single words. 
Mentally she scored equivalent to age 25 months at the age of 50 months (4 years 2 months), with 
an IQ in the range of 35-49, placing her in the moderate group of intelligence disability.  The 
diagnosis of autism spectrum disorder was made at the age of 3 years. Cerebral echography and 
MRI could not detect any abnormalities. Previously performed array-CGH (1Mb resolution) was 
normal. 
 
Figure 1  
Clinical pictures at the age of 2 years and 5 years showing mild dysmorphic facial features: 
bitemporal narrowing, arched and laterally extended eyebrows, mild upslanting palpebral fissures, 
deep set eyes, a tented upper lip, thin upper vermilion and full lower vermilion. Pectus excavatum 
is most likely due to cardiac surgery performed at a young age. 
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MATERIALS AND METHODS 
EXOME ANALYSIS 
Informed consent for trio analysis by exome analysis was obtained from the parents. Library 
construction for all samples were prepared using TruSeq DNA Library Preparation Kit (Illumina, 
Inc., San Diego, CA, USA) in which platform-specific adaptors and unique DNA indexes were 
ligated. For each sample, 1 µg genomic DNA was sheared by sonication to approximately 300bp 
fragments, followed by end-repair, adenylation and adapter ligation steps. DNA sequencing 
libraries were subsequently enriched with the SeqCap EZ Human Exome Library v3.0 (Roche, 
NimbleGen), and 2 × 100-bp paired-end reads were generated on the Illumina HiSeq2000 platform 
with 3-4 exome-seq samples pooled per lane of a sequencing flow-cell.  Sheared DNA, whole 
genome libraries and enriched exome-seq libraries were validated using DNA-1000 chips on the 
BioAnalyser (Agilent), and library concentrations were determined using the dsDNA Broad Range 
Assay using the Qubit (Invitrogen). 
Data analysis was done using commercial and in-house developed software (Genomics Core/UZ 
Leuven). Exome sequences were obtained from both parents and the patient. As our hypothesis 
was a de novo mutation, the patient was filtered against all in-house (n=72) exomes, allowing the 
exclusion of local rare variants. All non-reference calls were excluded in the parents, reference 
calls were excluded in the patient. According to Ensembl (www.ensemble.org) only exonic, 
exonic/splicing and splicing variants were included. Synonymous variants were excluded. Variants 
occurring with a frequency of <1% in the 1000 genomes project or with an unknown frequency 
were included. Variants occurring in HLA and MUC genes were excluded. Splicing site changes 
occurring at less than 5 positions were considered as possible candidates. 
 
RESULTS 
EXOME SEQUENCING 
After variant filtering as outlined in the methods section, we identified variants in 48 candidate 
genes (Table IS). This gene list was manually curated using functional data and genotype-
phenotype correlations for the implicated genes. We thus identified a de novo non-frameshift 
deletion of three base pairs in the MEIS2 gene NM_170674.2 c.998_1000del:p.Arg333del as the 
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most likely cause. This causes a deletion of three nucleotides GAA and thus deletion of the amino 
acid Arginine (Arg). Results were confirmed by Sanger sequencing (Figure 2). 
 
 
Figure 2  
Sanger sequencing of the patient, father and mother showing a de novo non-frameshift deletion in 
the patient of three base pairs in the MEIS2 gene. 
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DISCUSSION 
We report the first patient who carries a small intragenic mutation in the MEIS2 gene, confirming 
the previous association of MEIS2 with cleft palate and cardiac septal defects. No other in-frame 
deletions or point mutations have been described until now. Of interest, the present patient had 
moderate ID, severe gross motor delay and autism spectrum disorder. Previously reported 
patients with an intragenic MEIS2 deletion also had delayed motor development, but varying 
degrees of delay in mental development, ranging from normal to moderate. One of these patients 
also suffered from autism spectrum disorder as diagnosed in our patient, albeit with a mild ID and 
without cleft palate or cardiopathy [Johansson et al., 2014] Table 1. 
MEIS2 is a transcription factor and most likely has a role in the stabilization of the 
Homeoprotein-DNA complex. It binds to HOX or PBX proteins to form dimers and 
multimers. The arginine residue deleted is located in the homeodomain. This single amino 
acid deletion could therefore interfere with DNA binding. Arg333 is highly conserved across 
all species and isoforms. In addition, according to the Protein Databank in Europe 
(PDBePISA) database, the Arg residue mutated in the present patient is involved in a 
multimer contact [Krissinel et al., 2007; (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html)]. 
Any hydrogen bonds that could be made by the wild type residue to other monomers would 
therefore be lost and affect the multimeric compound. Therefore, the more pronounced ID 
observed in the present patient may possibly be due to another mechanism than merely 
haploinsufficiency. Thus, the deletion of the Arg residue may have an additional dominant 
negative effect. 
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Case 
num
ber 
Sex 
Chrom
osom
al aberration 
Genes involved 
Cardiac m
alform
ation 
Clefting 
M
ental developm
ent 
1 
F 
5.3 M
b del 
ACTC, GREM
1, CX36, M
EIS2, 
ARHGAP11A, CHRNA7, CHRM
5 
ASD II 
palate 
severe speech delay, m
ild m
otor delay 
2 
M
 
5.6 M
b del 
M
EIS2, m
any other genes 
VSD 
palate 
delayed, epilepsy 
3 
M
 
123 kb del 
M
EIS2 
VSD 
cleft soft palate 
bilateral m
oderate hearing loss 
4 
F 
58 kb dup 
M
EIS2 
none 
subm
ucous cleft palate 
m
ild ID 
5 
F 
58 kb dup 
M
EIS2 
none 
subm
ucous cleft palate 
delayed 
6 
M
 
58 kb dup 
M
EIS2 
none 
open cleft palate 
delayed 
7 
F 
58 kb dup 
M
EIS2 
none 
open cleft palate 
m
ild ID 
8 
F 
0.6 M
b del 
C15orf41, CSNK1A1P1, M
EIS2 
VSD 
open cleft palate 
norm
al 
9 
M
 
0.6 M
b del 
C15orf41, CSNK1A1P1, 
LO
C145845, M
EIS2 
none 
bilateral cleft lip and 
palate 
delayed 
10 
M
 
1.0 M
b del 
C15orf41, CSNK1A1P1, 
LO
C145845, M
EIS2 
none 
none 
m
ild ID, ASD 
11 
M
 
1.9 M
b del 
C15orf41, CSNK1A1P1, 
LO
C145845, M
EIS2, TM
CO
5A, 
SPRED1, FAM
98B, RASGRP1, 
C15orf53 
VSD 
none 
delayed 
12 
F 
4.8 M
b del 
C15orf41, CSNK1A1P1, 
LO
C145845, M
EIS2, TM
CO
5A, 
SPRED1, FAM
98B, RASGRP1, 
C15orf53, C15orf54 
VSD 
subm
ucous cleft palate, 
bifid uvula 
delayed 
13 
F 
c.998_1000del: p.Arg333del  
M
EIS2 
ASD II, VSD, LVO
TO
, 
CoA 
soft and hard cleft 
palate 
severe gross m
otor and verbal delay, ASD 
 Table 1 
M
ain phenotypic features and involved genes of patients w
ith M
EIS2 haploinsufficiency.
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Functional studies showed that MEIS2B, one of two orthologs of MEIS2 in zebrafish, is important in 
heart formation, regulation and function. Knockdown of MEIS2B in zebrafish embryos lead to 
defective cardiac morphogenesis with no midline formation of the linear heart tube, severe 
defects in heart looping, pericardial edema and a significantly reduced heart rate [Paige et al., 
2012; Glickman et al., 2002]. Interestingly, expression of MEIS2B in the heart field of developing 
mutant zebrafish embryos closely resembles that of GATA4, a known cardiac transcription factor 
[Paige et al., 2012]. Mutations in GATA4 are well-known in causing primarily cardiac septal defects, 
ranging from ASD and VSD to atrio-ventricular septal defects (AVSD) [Garg et al., 2003]. Regarding 
ID and developmental delay; MEIS2B expression is observed in the developing hindbrain of 
somites [Zerucha et al., 2001], and MEIS2 is a principal key factor in patterning of the hindbrain 
[Waskiewicz et al., 2001] as well as normal mesencephalic development in mice and chick embryos 
[Shim et al., 2007; Agoston et al., 2009; Vennemann et al., 2008]. 
This case report builds on the previous publications that MEIS2 should be considered in patients 
with cleft palate, septal cardiac defects and ID.  Further functional studies regarding the role of 
MEIS2 in neuronal pathways and mental development will be necessary to explore the exact 
mechanisms involved in this intricate mechanism. 
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SU
PPLEM
EN
TARY O
N
LIN
E M
ATERIAL 
Table IS 
Rem
aining variants after filtering for heterozygous calls in the index and reference calls in both parents.  
Chr 
Start 
End 
Reference 
O
bserved 
G
ene 
AA Change 
Function 
Exonic function 
1 
152276671 
152276671 
C 
T 
FLG 
FLG
:N
M
_002016:exon3:c.G
10691A:p.R3564H 
exonic 
nonsynonym
ous SN
V 
1 
111957553 
111957553 
G 
T 
O
VGP1 
O
VGP1:N
M
_002557:exon11:c.C1570A:p.L524M
 
exonic 
nonsynonym
ous SN
V 
1 
111957558 
111957558 
T 
G 
O
VGP1 
O
VGP1:N
M
_002557:exon11:c.A1565C:p.K522T 
exonic 
nonsynonym
ous SN
V 
1 
111957561 
111957561 
T 
C 
O
VGP1 
O
VGP1:N
M
_002557:exon11:c.A1562G
:p.E521G 
exonic 
nonsynonym
ous SN
V 
1 
11584023 
11584023 
G 
T 
PTCHD2 
PTCHD2:N
M
_020780:exon11:c.G2387T:p.S796I 
exonic 
nonsynonym
ous SN
V 
2 
233712209 
233712209 
TCAG
CAG
CAG
CAG
CTG
CCACAG
 
T 
G
IGYF2 
G
IGYF2:N
M
_001103147:exon29:c.3676_3696del:p.1226_1232del 
exonic 
nonfram
eshift deletion 
2 
240982073 
240982073 
G 
C 
PRR21 
PRR21:N
M
_001080835:exon1:c.C327G
:p.C109W
 
exonic 
nonsynonym
ous SN
V 
2 
240982135 
240982135 
A 
G 
PRR21 
PRR21:N
M
_001080835:exon1:c.T265C:p.S89P 
exonic 
nonsynonym
ous SN
V 
2 
240982199 
240982199 
A 
C 
PRR21 
PRR21:N
M
_001080835:exon1:c.T201G
:p.C67W
 
exonic 
nonsynonym
ous SN
V 
2 
240982200 
240982200 
C 
T 
PRR21 
PRR21:N
M
_001080835:exon1:c.G200A:p.C67Y 
exonic 
nonsynonym
ous SN
V 
3 
171065010 
171065010 
G 
G
A 
TN
IK 
  
splicing 
  
3 
75832519 
75832519 
A 
G 
ZN
F717 
  
splicing 
  
3 
75832522 
75832522 
G 
T 
ZN
F717 
  
splicing 
  
4 
47033767 
47033767 
ATCTCG
C 
A 
G
ABRB1 
  
splicing 
  
4 
144922436 
144922436 
T 
G 
G
YPB 
G
YPB:N
M
_002100:exon2:c.A38C:p.E13A 
exonic;splicing 
nonsynonym
ous SN
V 
4 
59469 
59469 
A 
G 
ZN
F718 
  
splicing 
  
7 
142460428 
142460428 
CCAA 
C 
PRSS1 
  
splicing 
  
8 
144940706 
144940706 
C 
T 
EPPK1 
EPPK1:N
M
_031308:exon1:c.G
6716A:p.R2239H 
exonic 
nonsynonym
ous SN
V 
9 
35809214 
35809214 
G 
T 
N
PR2 
N
PR2:N
M
_003995:exon21:c.G3048T:p.Q
1016H 
exonic 
nonsynonym
ous SN
V 
9 
35683240 
35683240 
T 
TG 
TPM
2 
  
splicing 
  
10 
135439049 
135439049 
G 
C 
FRG2B 
FRG2B:N
M
_001080998:exon4:c.C391G
:p.P131A 
exonic 
nonsynonym
ous SN
V 
10 
50819952 
50819952 
G 
T 
SLC18A3 
SLC18A3:N
M
_003055:exon1:c.G
1166T:p.G
389V 
exonic 
nonsynonym
ous SN
V 
11 
48346541 
48346541 
A 
T 
O
R4C3 
O
R4C3:N
M
_001004702:exon1:c.A49T:p.T17S 
exonic 
nonsynonym
ous SN
V 
11 
48346547 
48346547 
C 
T 
O
R4C3 
O
R4C3:N
M
_001004702:exon1:c.C55T:p.P19S 
exonic 
nonsynonym
ous SN
V 
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Table 1S (continued) 
Chr 
Start 
End 
Reference 
O
bserved 
G
ene 
AA Change 
Function 
Exonic function 
11 
56468440 
56468440 
G 
T 
O
R9G
9 
O
R9G
9:N
M
_001013358:exon1:c.G
577T:p.G
193C 
exonic 
nonsynonym
ous SN
V 
12 
49994257 
49994257 
T 
G 
FAM
186B 
FAM
186B:N
M
_032130:exon4:c.A1166C:p.H389P 
exonic 
nonsynonym
ous SN
V 
12 
53069222 
53069222 
CACCTCCG
G
AG
CCG
TAG
CTG
CT 
C 
KRT1 
KRT1:N
M
_006121:exon9:c.1669_1689del:p.557_563del 
exonic 
nonfram
eshift deletion 
12 
11183541 
11183541 
T 
C 
TAS2R31 
TAS2R31:N
M
_176885:exon1:c.A394G
:p.M
132V 
exonic 
nonsynonym
ous SN
V 
13 
20279879 
20279879 
T 
C 
PSPC1 
PSPC1:N
M
_001042414:exon9:c.A1309G
:p.M
437V 
exonic 
nonsynonym
ous SN
V 
14 
19553586 
19553586 
T 
C 
PO
TEG 
PO
TEG
:N
M
_001005356:exon1:c.T170C:p.L57P 
exonic 
nonsynonym
ous SN
V 
15 
79067065 
79067065 
G 
A 
ADAM
TS7 
ADAM
TS7:N
M
_014272:exon12:c.C1777T:p.P593S 
exonic 
nonsynonym
ous SN
V 
15 
72954577 
72954577 
C 
G 
G
O
LG
A6B 
  
splicing 
  
15 
37188864 
37188864 
ATTC 
A 
M
EIS2 
M
EIS2:N
M
_170674:exon10:c.998_1000del:p.333_334del 
exonic 
nonfram
eshift deletion 
16 
67424209 
67424209 
G 
T 
TPPP3 
TPPP3:N
M
_016140:exon5:c.C399A:p.G
133G 
exonic 
nonsynonym
ous SN
V 
17 
38126911 
38126911 
AACACAC 
A 
G
SDM
A 
  
splicing 
  
17 
39296412 
39296412 
T 
A 
KRTAP4-6 
KRTAP4-6:N
M
_030976:exon1:c.A328T:p.S110C 
exonic 
nonsynonym
ous SN
V 
17 
39253949 
39253949 
T 
A 
KRTAP4-8 
KRTAP4-8:N
M
_031960:exon1:c.A388T:p.S130C 
exonic 
nonsynonym
ous SN
V 
17 
39253953 
39253953 
G 
T 
KRTAP4-8 
KRTAP4-8:N
M
_031960:exon1:c.C384A:p.S128R 
exonic 
nonsynonym
ous SN
V 
17 
39254126 
39254126 
C 
T 
KRTAP4-8 
KRTAP4-8:N
M
_031960:exon1:c.G
211A:p.V71M
 
exonic 
nonsynonym
ous SN
V 
17 
39254133 
39254133 
G 
T 
KRTAP4-8 
KRTAP4-8:N
M
_031960:exon1:c.C204A:p.S68R 
exonic 
nonsynonym
ous SN
V 
17 
78897395 
78897395 
C 
A 
RPTO
R 
RPTO
R:N
M
_020761:exon23:c.C2730A:p.G
910G 
exonic 
nonsynonym
ous SN
V 
19 
42795827 
42795827 
G 
C 
CIC 
CIC:N
M
_015125:exon11:c.G
2816C:p.G
939A 
exonic 
nonsynonym
ous SN
V 
19 
7935863 
7935863 
G 
T 
FLJ22184 
U
N
KN
O
W
N
 
exonic 
nonsynonym
ous SN
V 
19 
50826910 
50826910 
G 
T 
KCN
C3 
KCN
C3:N
M
_004977:exon2:c.C1300A:p.L434M
 
exonic 
nonsynonym
ous SN
V 
19 
13936534 
13936534 
G 
T 
ZSW
IM
4 
  
splicing 
  
20 
26061859 
26061859 
G 
T 
FAM
182A 
  
exonic 
stopgain SN
V 
20 
62655943 
62655943 
C 
A 
PRPF6 
PRPF6:N
M
_012469:exon14:c.C1805A:p.A602D 
exonic 
nonsynonym
ous SN
V 
X 
140993695 
140993695 
G 
T 
M
AG
EC1 
M
AG
EC1:N
M
_005462:exon4:c.G
505T:p.A169S 
exonic 
nonsynonym
ous SN
V 
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CHAPTER 4 
IDENTIFICATION OF THE GENETIC CAUSE OF FAMILIAL 
SYNDROMIC CARDIOPATHIES AND RARE TYPES OF 
CARDIOMYOPATHY 
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ABSTRACT 
We studied five small families with two affected siblings but unaffected parents with a familial 
form of congenital syndromic cardiopathy or a rare cardiomyopathy. 
Genetic analysis was done using linkage analysis in the parents and both the unaffected and 
affected siblings, followed by whole exome sequencing (WES). WES was done in the affected 
siblings only of Family 1 and 2, and in all family members of Families 3, 4 and 5. Data analysis was 
done using commercial and in-house developed software. Only variants in genes from the linkage 
regions were retained. Variant analysis was done according to the hypothesis of different possible 
inheritance patterns (autosomal recessive, dominant with parental mosaicism and X-linked).  
In the two families with a rare type of cardiomyopathy, a genetic cause was identified. 
Homozygous mutation of ALMS1 explained the mitogenic cardiomyopathy phenotype, and was 
confirmed by another group studying unrelated families. We identified novel compound 
heterozygous mutations in KIF20A as the cause of a lethal form of restrictive cardiomyopathy of 
the right ventricle. Functional and zebrafish studies supported a role for this gene in the observed 
phenotype. In the three other families with a syndromic type of CHD, no genetic cause was 
identified, suggesting that current genetic analysis tools lack the sensitivity to identify all possible 
mutations.  
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INTRODUCTION 
Familial CHD represents about 4% of all CHD’s. The majority of these are non-syndromic [1-5], 
and genetic testing can often identify the causal genetic mutation, especially in large families [6]. 
Familial syndromic CHD is very rare and occurs in around 1% of all CHD. In some instances, the 
syndrome occurs in different generations: when it is mild and inherited as an autosomal dominant 
disorder (e.g. Holt-Oram syndrome or Noonan syndrome) or when transmitted through an 
unaffected female in X-linked recessive disorders (e.g. Barth syndrome, Duchenne or Becker 
muscular dystrophy). However, most syndromes are severe and have a reduced reproductive 
fitness, due to the severity of the disorder or the associated intellectual disability. This typically 
results in sporadic syndromic CHD (S-CHD) due to a de novo mutation, as discussed in chapter 3. 
In this chapter, we study five small families with two siblings affected with a severe, syndromic 
CHD or with a lethal, exceptional type of cardiomyopathy. These very rare and specific 
phenotypes are likely to have a monogenic cause. In these families, in contrast to large non-
syndromic families, no clinical diagnosis could be reached which could orient our genetic analyses. 
This is because the combination of distinct anomalies observed in the siblings does not fit a known 
entity, and thus constitute a new unknown syndrome [7]. Alternatively, the cardiac phenotype is 
unique, e.g. an early onset/neonatal cardiomyopathy (CM) with unknown genetic cause. In these 
families, the inheritance pattern is most likely autosomal recessive (AR), especially when the 
parents are consanguineous and sometimes X-linked (when the affected siblings are males). 
Germline or low grade somatic mosaicism in one parent for an AD disorder should also be 
considered (Figure 1).  
We evaluated to what extent exome sequencing in combination with linkage analysis allowed us 
to identify the causative genes in these small families.  
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Figure 1. Possible modes of inheritance in families with unaffected parents and affected 
siblings. Mutations in genes are shown as paternal (blue) or maternal (pink). Mutations are 
detected in DNA of white blood cells (WBC) and inherited as autosomal recessive (AR) or X-linked 
recessive disorders, or can be present in DNA of germline cells and thus inherited as an autosomal 
dominant (AD) disorder. 
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MATERIALS AND METHODS 
Patient selection and description 
We analysed 5 families followed in the pediatric cardiology department and Center for Human 
Genetics in our tertiary hospital.  
 
Inclusion criteria 
1. Syndromic CHD or a rare cardiomyopathy with syndromic defined as the presence of 1 
additional major abnormality apart from the CHD, or intellectual disability not otherwise 
explained and/or dysmorphism, defined as 3 or more minor anomalies. 
2. An unknown cause after extensive evaluation: 
* All patients were examined by an experienced clinical geneticist and clinical pictures were 
available for discussion with other clinical geneticists and for review of the phenotype in case a 
mutation was found. Clinical information on the parents and unaffected sibling were available.  
* High resolution array-CGH was normal in the patients and parents and showed no unclassified 
variants. 
3. DNA was available from the patients, both parents and the unaffected sibling.  
5. No external causes identified: no teratogens during pregnancy, no other known cause for 
neurological damage.  
The study was approved by the Ethical Committee University Hospital Leuven (S52853 – 
B322201010111). Informed consent was obtained from all parents.  
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 Fam
ily  
Sibling 
Gender 
Result 
Age 
CHD 
ID
 
O
ther m
ajor 
m
alform
ations 
M
inor 
m
alform
ations 
HC 
(SDS) 
W
eight 
(SDS) 
Height 
(SDS) 
O
ther 
1 
1 
M
 
ALM
S1 
0 
M
CM
 
N
A 
none 
none 
2,5 
-0,8 
3,0 
 
1 
2 
F 
ALM
S1 
0 
M
CM
 
N
A 
none 
none 
N
A 
1,6 
-1,8 
 
2 
1 
M
 
KIF20A 
0 
RCM
 
N
A 
none 
none 
-0,5 
-0,2 
1,0 
 
2 
2 
F 
KIF20A 
0 
RCM
 
N
A 
none 
none 
0,5 
1,3 
0,9 
 
3 
1 
M
 
 
4,9 
M
S,AS, 
LVO
TO
 
M
ild 
unilateral renal 
agenesis, kyphosis 
facial 
dysm
orphism
 
0,9 
-2,5 
-3,4 
strabism
us 
3 
2 
F 
 
1,5 
AS, LVO
TO
 
M
ild 
Situs inversus totalis 
facial 
dysm
orphism
 
3,3 
-0,2 
-0,8 
strabism
us 
4 
1 
F 
 
5,2 
VSD 
S 
grow
th retardation, 
bilateral postaxial 
polydactyly, atlanto-
occipital fusion, 
colobom
a, hypoplastic 
right kidney 
facial 
dysm
orphism
 
-2,5 
-5 
-3,5 
frequent respiratory 
infections, nystagm
us, 
ectopic neuropituitary 
gland 
4 
2 
F 
 
0,3 
VSD, ASD II, 
PS 
N
A 
(deceased) 
bilateral postaxial 
polydactyly, hypoplasia 
verm
is 
facial 
dysm
orphism
 
N
A 
-1,4 
N
A 
ectopic neuropituitary 
gland, enlarged 
cisterna m
agna 
5 
1 
M
 
 
4,2 
ASD II 
M
ild 
agenesis ductus 
venosus 
pectus carinatum
, 
facial 
dysm
orphism
, 
bilateral palm
ar 
sim
ian crease 
-0,8 
-3,7 
-3,7 
feeding problem
s, 
neutropenia during 
infancy, O
SAS 
5 
2 
M
 
 
0,2 
ASDII 
N
L 
none 
facial 
dysm
orphism
, 
bilateral palm
ar 
sim
ian crease 
-2,3 
-2,7 
-3,6 
 
 Table 1 
Clinical data of the five fam
ilies.  
Colum
ns show
 fam
ily num
ber, sibling num
ber, gender, genetic result, age at exam
ination, type of CHD, level of ID, other m
ajor m
alform
ations, description of m
inor 
anom
alies, biom
etry and other characteristics. Level of ID at age of exam
ination w
as norm
al (N
L), m
ild, m
oderate (M
) and severe (S). CHD included m
itogenic 
cardiom
yopathy (M
CM
), restrictive cardiom
yopathy (RCM
), m
itral stenosis (M
S), aortic stenosis (AS), left ventricular outflow
 tract obstruction (LVO
TO
), atrial 
septal defect type secundum
 (ASD II), ventricle septal defect (VSD) and pulm
onary stenosis (PS). Head Circum
ference (HC), w
eight and height is given as standard 
deviations. O
bstructive sleep apnea syndrom
e (O
SAS). Som
e data w
as not available (N
A), m
ostly due to the young age at w
hich evaluation of neurologic 
developm
ent w
as not possible.
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Figure 2. Pedigrees of the 5 families studied. 
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Family 1 
Two siblings from consanguineous parents of Turkish descent (Figure 2, Family 1) presented with 
an isolated dilated cardiomyopathy leading to early death in infancy. The diagnosis of a rare 
cardiomyopathy i.e. mitogenic cardiomyopathy was made histologically. The clinical and genetic 
findings in this family are described in detail in annex Chapter 4.1. 
Family 2 
Two siblings, one male and one female (Figure 2, Family 2), were diagnosed in late fetal life with a CHD 
categorized as restrictive cardiomyopathy (RCM) of the right ventricle (RV). An older sibling and both non-
consanguineous parents had a normal phenotype. Both affected children demised in infancy at the ages 
of respectively 3 and 2 months due to progressive and fatal cardiac failure. The clinical and genetic findings 
in this family are described in detail in annex Chapter 4.2. 
Family 3 
This was a non-consanguineous Caucasian family with two affected children (Figure 2, Family 3). 
The index patient had a complex CHD which required multiple cardiac interventions. The CHD 
consists of a Shone-complex characterized by an arcade mitral valve (MV) with dysplastic and 
thickened valve leaflets, a smaller annulus and short MV chordae. There was aortic stenosis due 
to a small bicuspid aortic valve, thickened leaflets as well as subvalvular aortic stenosis. He had 
mild ID and facial dysmorphism with anteversion of the nares, strabismus, bright blue irides, small 
ears, epicanthic folds, a tented upper lip and full cheeks. He had unilateral renal agenesis, lumbar 
kyphosis and a short neck. There was excessive keloid formation after cardiac surgery which 
required surgical resection.  
His younger sister was born at term (PMA 39 weeks) with a weight of 3,56 kg (SD + 0,4) and a 
head circumference of 36 cm (SD – 0,5). Prenatally there was polyhydramnion; additionally the 
diagnosis of situs inversus totalis was made as well as a mild aortic stenosis. This progressed 
postnatally to a multilevel and complex CHD: a dysplastic mitral valve with thick, muscular 
chordae, a dysplastic tricuspid aortic valve, severe subvalvular aortic stenosis with a subvalvular 
ridge, and hypertrophic cardiomyopathy for which multiple and complex cardiac surgeries were 
necessary. She has mild ID and the same facial dysmorphic features and strabismus as her older 
brother as well as macrocrania with a head circumference of 51,5 cm (SD + 3.3) at the age of 1,5 
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years. In the two siblings, chromosomal analysis by means of array comparative genomic 
hybridization (CGH) was performed using the 180k CytoSure ISCA v2 microarray (Oxford Gene 
Technology, OGT, Oxford, UK). No pathogenic chromosomal variants or recurrent chromosomal 
variants of unknown significance were detected (Table 2, Family 3). 
 
 
 
Figure 3. Clinical findings in two siblings of family 3. 
Note the similar facial features in the index (A & B) and his younger sister (D & E). Cardiac 
ultrasound images show the mitral valve with dysplastic and thickened valve leaflets and chordae 
in the index (C) and multilevel left ventricular outflow tract obstruction with a small LVOT 
(crosses) and subvalvular ridge (arrows) as well as LV hypertrophy. 
 
B C 
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Family 4 
The clinical findings in family 4 have been reported before [7]. In short, this was a non-
consanguineous family (Figure 2, family 4) with three children. The index was born at term, with 
birth weight 2640 g (SD -2,1), length 44 cm (SD -3,5) and head circumference 31.5 cm (SD -3). She 
had bilateral postaxial polydactyly of the hands, a perimembranous VSD and a right renal 
hypoplasia. She had upslant of the eyes, hypoplasia of the nasal bridge, anteversion of the 
nostrils, a long and smooth philtrum, a narrow vermillion of the upper lip and a prominent lower 
lip vermillion with a swelling on the right side (Figure 3A). She had temporal balding with coarse 
and brittle hair as well as a hemangioma on the scalp. The nipples were wide set and the feet 
were oedematous. She had a severe growth delay: at age of 19 months, weight was 7.8 kg (SD -
3,4), length 70.5 cm (SD -4,0) and head circumference 44.9 cm (SD -1,7). There was a small 
coloboma of the left eye. She had an ectopic neuropituitary gland but no endocrine disturbance 
was observed (Figure 4E). She had torticollis due to an atlanto-occipital fusion and partial fusion 
of C2-C3. She had a severe ID. She also had frequent respiratory infections. She had a viral 
myocarditis at the age of 5 years after surgical closure of the VSD with secondary dilated 
cardiomyopathy. This evolved to a chronic, but stable, mild cardiac dysfunction with a fractional 
shortening of 27% (normal >30%) under cardiac failure medication. 
Her younger sister was born after an uneventful pregnancy at a gestational age of 32 weeks, with 
a birth weight of 1.2 kg (SD -1,4), length of 37.5 cm (SD -2,0) and head circumference of 26 cm 
(SD – 1,8). She had a VSD with pulmonary stenosis and an ASD II. Postaxial polydactyly of both 
hands was present. The facial features were almost identical to that of her sister (Figure 4B and 
4D). Magnetic resonance imaging of the brain also revealed an ectopic neuropituitary gland, and 
a normal to slightly enlarged posterior fossa associated with an enlarged cisterna magna and mild 
hypoplasia of the cerebellar vermis. Endocrine studies during the first months of life revealed 
normal thyroid and adrenal function, and normal growth hormone levels. She died at the age of 
4 months from postoperative complications after cardiac surgery. 
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Figure 4. Clinical findings in the two affected siblings from family 4. 
Note the similar features in the index (A&C) and her younger sister (B&D). Cerebral magnetic 
resonance imaging (E) of the index showing the ectopic neuropituitary gland as indicated by the 
arrow. 
  
Family 5 
The index patient was born at term as the first child of non-consanguineous Caucasian parents 
(Figure 2, family 5). At birth he had a weight of 2, 13kg (SD -3.3), length of 45 cm (SD -2,5) and 
head circumference of 32cm (SD -1,64). During infancy he had recurrent severe infections due to 
a transient neutropenia. There was a prenatal diagnosis of agenesis of the ductus venosus, 
drainage of the umbilical vein occurred through extrahepatic veins to the right atrium. The heart 
was displaced to the left, horizontal and posterior. The diagnosis of a fenestrated ASD II was made 
A 
C 
B 
D E 
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which closed spontaneously. The umbilicus was implanted to the left and he had pectus 
carinatum. He had facial dysmorphic features with anteversion of the nostrils, retrognathia and 
short palpebral fissures. He had a bilateral palmar simian crease. He had mild intellectual 
disability, and more pronounced gross motor delay. He had obstructive sleep apnea syndrome 
(OSAS). 
 
His younger brother had a milder phenotype. He had a small stature with weight 4,3 kg (SD -2,7), 
height 52cm (SD – 3,6) and head circumference of 38 cm (SD – 2,3) at the age of 2 months. He 
had the same facial dysmorphic features and a small ASD II which closed spontaneously in the 
first year of life. He had no neutropenia. At the age of 2 months, no signs of major developmental 
difficulties were observed.  
 
 
 
Figure 5. Clinical findings in the two brothers from Family 5. 
Note the similar facial phenotype in the index (B) and his younger brother (A). 
 
A B 
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Exome sequencing 
WES was done by the Genomics Core KU Leuven/UZ Leuven as described in Chapter 3. 
In the affected siblings of family 4 and 5 the WES analysis was done in collaboration with the 
Human Genome Sequencing Center (HGSC) at Baylor College of Medicine through the Baylor-
Hopkins Center for Mendelian Genomics initiative in an Index-only analysis. Whole exome 
sequencing was performed at the HGSC as described previously in chapter 3 [8-10]. 
 
Linkage analysis 
Genotyping was done on DNA extracted from peripheral white blood cells, obtained from the 
parents and both the unaffected and affected siblings. A dense SNP marker set derived from the 
250k Affymetrics SNP typing platform was used in a recessive model in all families and in the 
family with two affected males an X-linked model was also done. Genome wide parametric 
linkage analysis with Merlin software was performed  
(http://www.sph.umich.edu/csg/abecasis/Merlin/tour/parametric.html). 
 
Variant filtering 
Exome sequences were obtained from both parents and the patient. VCF files were converted 
into Excel files, all further filtering was done manually. We analyzed variants with quality class 1 
and 2 as described in chapter 3. In the families with a cardiomyopathy, we first selected a panel 
of known CM genes from the exome to specifically exclude mutations in these genes. Likewise, in 
family 4 mutations in known ciliopathy genes were specifically evaluated [11].  
We excluded all variants that were homozygous in one of the parents or in the unaffected sibling. 
Variants that were homozygous reference in the affected siblings were excluded. Only exonic and 
splicing variants were included, synonymous variants were excluded. Variants occurring with a 
frequency of <5% in the 1000 genomes project or with an unknown frequency were included.  
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1.1. Autosomal recessive inheritance   
We only retained candidate genes located in the linkage regions for which the parents and the 
unaffected sibling were either heterozygous or reference. 
 
1.1.1. Homozygous inheritance 
The patients were filtered against 72 local exomes, i.e. retaining variants for which only the 
patients were homozygous. In-silico predictions and manual curation of the remaining variants 
were done as described previously. 
 
1.1.2. Compound heterozygous inheritance 
Firstly, the patients were filtered against 72 local exomes, i.e. excluding variants that were 
homozygous in these control exomes. All heterozygous calls were included in the parents, 
homozygous calls were excluded in the unaffected sibling. Remaining variants were manually 
filtered according to one paternal and one maternal inherited variant occurring in the same gene. 
In-silico predictions and manual curation of the remaining variants were done as described above. 
 
1.2. X-linked hypothesis 
In the case of two male affected patients (family 5) the patients were first filtered against all in-
house (n=85) exomes, allowing the exclusion of local rare variants. All heterozygous variants 
occurring in other patients were thus excluded, only variants occurring in the X-chromosome 
were analyzed. Next, we filtered for variants that were wild-type (reference) in the father and 
heterozygous in the mother (obligatory heterozygous carrier). In a third step, we retained exonic 
nonsynonymous variants, exonic/splicing and intronic splicing variants occurring at less than 5 
positions from the splicing site. Next, we only retained variants occurring with a frequency of <1%, 
or with an unknown frequency, in the 1000 Genomes Project. In-silico predictions by Polyphen, 
Mutation Taster and SIFT were used with discretion as an additional filter when necessary, only 
variants predicted as damaging or disease causing by 2 or more in-silico tools were further 
analysed. The remaining list was manually curated with literature using UCSC, OMIM, Pubmed 
and Genetools. 
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1.3. Autosomal dominant inheritance due to germline mosaicism 
All variants were analysed and thus not only those in linkage regions, for the presence of a de 
novo variant shared by the two siblings. All heterozygous calls in the affected patients were 
included, only wild-type (reference) calls were included in the parents. We retained exonic 
nonsynonymous variants, exonic/splicing and intronic splicing variants occurring at less than 5 
positions from the splicing site. Next, we only retained variants occurring with a frequency of <1%, 
or with an unknown frequency, in the 1000 Genomes Project. In-silico predictions by Polyphen, 
Mutation Taster and SIFT were used with discretion as an additional filter when necessary, only 
variants predicted as damaging or disease causing by 2 or more in-silico tools were further 
analysed. The remaining list was manually curated with literature using UCSC, OMIM, Pubmed 
and Genetools. 
 
RESULTS 
In the three families with syndromic CHD in two siblings, no causative mutation was identified. 
Following the hypothesis of autosomal recessive inheritance, we identified several candidate 
genes carrying two (mostly) missense variants inherited from both parents in all families, or one 
variant inherited from the mother in family 5 with two affected boys according to the X-linked 
autosomal recessive hypothesis (Table 2).  For none of these genes, there was convincing 
evidence to pursue further functional testing. Under the hypothesis of de novo dominant 
inheritance with germline mosaicism in one of the parents, no good candidate genes were 
identified.  
 
Table 2. Candidate genes and variants identified in three unsolved families.  
Variants obtained in the possible inheritance mechanisms: autosomal recessive (AR), autosomal 
dominant (AD) and X-linked recessive (XL). Variants in the affected patients are either 
homozygous (Hom), heterozygous (Het) or hemizygous (Hemi). NS: nonsynonymous, FS: 
frameshift. In-silico scores are given as a score out of 3 as predicted by AV-SIFT, Polyphen and 
Mutation Taster. OMIM disease indicates whether mutations in this gene have been implicated 
in a recognized OMIM disorder.  
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Family Mode of inheritance Gene Mutation Mutation Variant Function In-silico (N) OMIM disease
CIDEC NM_001199551:exon7:c.C630T:p.H210H Hom NS- SNV 1
Lipodystrophy, partia l  
fami l ia l  type 5 (AR)
ENGASE NM_001042573:exon7:c.G962A:p.R321H Hom NS- SNV 3
EXPH5 EXPH5:NM_015065:exon6:c.T3931C:p.C1311R Hom NS- SNV 1
Epidermolys is  bul losa  
(AR)
PKD1 NM_001009944:exon45:c.C12176T:p.A4059V Het NS- SNV 1
Adult polycystic kidney 
disease 1 (AD)
PKD1 NM_001009944:exon10:c.C2081T:p.P694L Het NS- SNV 3
GSTM5 NM_000851:exon4:c.G199A:p.A67T Het NS- SNV 0
GSTM5 GSTM5:NM_000851:exon8:c.A649G:p.S217G Het NS- SNV 0
BCR NM_004327:exon19:c.3274_3275insCCGG:p.S1092fs Het FS- insertion 0
OR2T2 NM_001004136:exon1:c.C310T:p.L104F Het NS- SNV 0
TPTE2 NM_001141968:exon5:c.T98G:p.L33R Het NS- SNV 1
VCX3A NM_016379:exon3:c.475_504del:p.159_168del Het nonFS- deletion 0
CCDC138 NM_144978:exon4:c.G295T:p.D99Y Hom NS- SNV 1
COL15A1 NM_001855:exon11:c.C1592G:p.P531R Hom NS- SNV 2
CRIPAK NM_175918:exon1:c.295_323del:p.99_108del Hom FS- deletion 0
DNAJC13 NM_015268:exon43:c.A5018G:p.Y1673C Hom NS- SNV 0
HLA-DRB5 NM_002125:exon5:c.C780A:p.H260Q Hom NS- SNV 0
KRTAP5-10
NM_001012710:exon1:c.276_277insGGCTGTGGCTCCTG
TGGGGGCTCCAAGGGA:p.G92delinsGGCGSCGGSKG Hom nonFS- insertion 0
MAPK6 NM_002748:exon5:c.C868G:p.L290V Hom NS- SNV 2
PRAMEF13
PRAMEF13:NM_001024661:exon4:c.G1276A:p.D426N,
PRAMEF14:NM_001099854:exon4:c.G1132A:p.D378N Hom NS- SNV 0
PRDM9 PRDM9:NM_020227:exon11:c.C2042G:p.T681S Hom NS- SNV 0
TNXB TNXB:NM_019105:exon43:c.G12541A:p.A4181T Het NS- SNV 2
Ehlers -Danlos  S. due 
to Tenascin-X 
deficiency (AR; AD)
TNXB TNXB:NM_019105:exon43:c.G12514A:p.D4172N Het NS- SNV 2
KMT2C MLL3:NM_170606:exon18:c.G2963T:p.C988F Het NS- SNV 3
KMT2C MLL3:NM_170606:exon18:c.T2959C:p.Y987H Het NS- SNV 3
KMT2C MLL3:NM_170606:exon14:c.G2512A:p.G838S Het NS- SNV 3
KMT2C MLL3:NM_170606:exon7:c.C871T:p.L291F Het NS- SNV 2
AD OR4A16 NM_001005274:exon1:c.C958A:p.P320T Het NS- SNV 0
BEND2 NM_153346:exon5:c.G586A:p.E196K Hom NS- SNV 3
VSIG4 NM_007268:exon2:c.G274T:p.V92F Hom NS- SNV 2
SHROOM3 NM_020859:exon5:c.G3160T:p.V1054L Hom NS- SNV 2
COL4A6 NM_033641:exon42:c.C4232G:p.P1411R Hom NS- SNV 2
ARSD NM_001669:exon6:c.G992A:p.W331X Het stopgain SNV 2
ARSD NM_001669:exon6:c.G959A:p.G320D Het NS- SNV 2
PABPC3 NM_030979:exon1:c.G532A:p.E178K Het NS- SNV 2
PABPC3 NM_030979:exon1:c.G541A:p.A181T Het NS- SNV 2
PABPC3 NM_030979:exon1:c.G617A:p.R206H Het NS- SNV 2
PABPC3 NM_030979:exon1:c.C619T:p.L207F Het NS- SNV 2
PABPC3 NM_030979:exon1:c.A691G:p.K231E Het NS- SNV 2
PABPC3 NM_030979:exon1:c.C832T:p.R278C Het NS- SNV 3
PABPC3 NM_030979:exon1:c.C874T:p.Q292X Het stopgain SNV 2
PABPC3 NM_030979:exon1:c.C956T:p.T319I Het NS- SNV 2
PABPC3 NM_030979:exon1:c.G1033T:p.E345X Het stopgain SNV 2
PRSS3 NM_001197097:exon4:c.A367C:p.M123L Het NS- SNV 2
PRSS3 NM_001197097:exon4:c.G458C:p.C153S Het NS- SNV 3
GXYLT1 NM_173601:exon3:c.T444G:p.H148Q Het NS- SNV 3
GXYLT1 NM_173601:exon3:c.A378T:p.R126S Het NS- SNV 3
SLC25A5 NM_001152:exon2:c.A230C:p.N77T Het NS- SNV 2
SLC25A5 NM_001152:exon2:c.A235T:p.I79F Het NS- SNV 2
SLC25A5 NM_001152:exon3:c.G707C:p.R236P Het NS- SNV 3
NOTCH2 NM_024408:exon2:c.G112A:p.E38K Het NS- SNV 2
Alagi l le S (AD);  Hadju-
Cheney (AD)
PPIAL4G NM_001123068:exon1:c.C302T:p.A101V Het NS- SNV 2  
NOTCH2NL NM_203458:exon4:c.C338T:p.P113L Het NS- SNV 2
NOTCH2NL NM_203458:exon4:c.C473T:p.T158I Het NS- SNV 3
NOTCH2NL NM_203458:exon4:c.C563A:p.P188H Het NS- SNV 2
NOTCH2NL NM_203458:exon4:c.A586T:p.T196S Het NS- SNV 2
HLA-B NM_005514:exon4:c.G703A:p.A235T Het NS- SNV 1
VCX3B NM_001001888:exon2:c.C7T:p.P3S Het NS- SNV 0
BEND2 NM_153346:exon5:c.G586A:p.E196K Hemi NS- SNV 3
COL4A6 NM_033641:exon42:c.C4232G:p.P1411R Hemi NS- SNV 2
RP2 NM_006915:exon3:c.C844T:p.R282W Hemi NS- SNV 0
TFDP3 NM_016521:exon1:c.T101C:p.V34A Hemi NS- SNV 0
UTP14A NM_006649:exon9:c.G766A:p.V256M Hemi NS- SNV 0
VCX NM_013452:exon2:c.C7T:p.P3S Hemi NS- SNV 1
VSIG4 NM_007268:exon8:c.C1148T:p.T383I Hemi NS- SNV 0
VSIG4 NM_007268:exon2:c.G274T:p.V92F Hemi NS- SNV 2
ZNF81 NM_007137:exon5:c.C554T:p.S185L Hemi NS- SNV 1
3
AR
AD
4 AR
5
AR
AD
XL
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A detailed description of the results in Family 1 and 2 as well as the additional functional and animal 
model studies are found in the annex to this chapter, 4.1 and 4.2 respectively. 
In Family 1, we identified 6 candidate genes in the linkage regions with homozygous mutations in 
the patient, inherited from both parents, and for which the unaffected sibling was heterozygous or 
reference. This gene list was manually curated using functional data and genotype-phenotype 
correlations for the implicated genes. We thus identified a deleterious mutation in the ALMS1 gene 
as the most likely cause. No additional mutations were found in known hypertrophic or dilated 
cardiomyopathy genes. The affected siblings were homozygous for a frameshift deletion of one 
basepair in the ALMS1 gene NM_015120.4:c.7760delG, p.Cys2587Phefs*5 
(NC_000002.11:g.73716849delG or NG_011690.1:g.108964del). This is predicted to cause a 
premature stop at position 5 downstream. The unaffected sister and parents are heterozygotes.  
Results were confirmed by Sanger sequencing. 
In Family 2 WES was performed on both affected siblings and the unaffected sibling. After filtering 
the variants in the 1273 genes in the linkage regions, under a hypothesis of autosomal recessive 
inheritance, we identified in KIF20A a maternal missense variant (c.544C>T: p.R182W), and a 
paternal frameshift mutation, creating a premature stop codon (c.1905delT: p.S635Tfs*15). The 
missense variant c.544C>T: p.R182W was predicted to be damaging by in silico tools SIFT, Polyphen 
and MutationTaster. These observations suggest that both variants are likely to affect protein 
function. Further functional testing was thus initiated to confirm pathogenicity, as described in 
Chapter 4.2. 
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DISCUSSION 
In this project, we were able to identify the genetic cause in 2 out of 5 small, likely autosomal or X-
linked recessive  families with an almost certain monogenetic cause of a syndromic CHD or distinct, 
lethal type of severe cardiomyopathy.  We thus identified two novel genetic causes of 
cardiomyopathy. First, mitogenic cardiomyopathy is the severe end of the spectrum of a well-known 
disorder, Alström syndrome. This is a very rare disorder (estimated incidence <1/1 000 000) [12], 
and cardiomyopathy is a known feature. In many academic hospitals targeted WES panels exist to 
screen for most known cardiomyopathies. These gene panels include known genes in hypertrophic-
, dilated-, restrictive- and Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). However, the 
ALMS1 gene usually is not in this panel, and therefore, this diagnosis would be missed.  
Next, we identified a novel type of restrictive cardiomyopathy of the right ventricle, and we provide 
extensive genetic and functional evidence that near complete loss-of-function mutations in the 
KIF20A gene cause this phenotype.  
In three families with a distinct phenotype, we did not identify a causal mutation. Several candidates 
were identified, but for none of them, functional knowledge on the gene indicated a causal mutation 
fitting the phenotype. One of the limitations is that these are unique families. The replication of a 
mutation in the same gene in unrelated individuals with the same phenotype is the cornerstone of 
gene identification. When no other families are known with the same disorder, replication is not 
possible, and we rely on functional tests. However, given the often large number of remaining 
candidate genes, this was not obvious.  
The question then remains how the genetic cause in these families will be resolved in the future? 
First, it is possible that, as for the mitogenic cardiomyopathy, other families will emerge with 
mutations in one of the implicated genes. Large collaborative studies generate a vast amount of 
genetic data, which can be interrogated through tools such as Gene Matcher [13, 14]. Also, the 
Deciphering Developmental Disorders consortium provides, in a Decipher Research track, all 
mutations found in genes for which currently there is not yet sufficient evidence that they are 
indeed developmental disorder genes. As an example, in the Decipher research track, two splice 
mutations are present in the MEIS2 gene, in patients with ID and cleft palate. Contacting the 
contributing clinicians can thus advance knowledge in this field. No mutations in KIF20A are listed. 
An alternative explanation is that the true genetic cause has been missed by the used technology. 
This is discussed in more detail in the final discussion of this thesis. WES is far from perfect to identify 
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all exonic mutations. In these three families, the average coverage of 20X was obtained in 82% of 
the target region (range 40-94%) meaning that around 18% of exons are not sufficiently covered. In 
addition, indels are often not called appropriately. Moreover, CNV’s too small to be detected by 
array-CGH but too large to be detected in WES will also be missed. We anticipate that future re-
assessment of these families using WGS has a good chance of identifying the causative mutation.  
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CHAPTER 4.1 
Homozygous loss-of-function mutation in ALMS1 causes the 
lethal disorder mitogenic cardiomyopathy in two siblings 
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Peeters, Philippe Moerman,  Koenraad Devriendt 
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ABSTRACT 
Background: Two siblings from consanguineous parents of Turkish descent presented with isolated 
dilated cardiomyopathy, leading to early death in infancy. The diagnosis of mitogenic 
cardiomyopathy was made histologically. 
Methods and results: Linkage analysis combined with exome sequencing identified a homozygous 
deleterious mutation in the ALMS1 gene as the cause of this phenotype. 
Conclusions: Alström syndrome is characterized by a typically transient dilating cardiomyopathy in 
infancy, suggesting that mitogenic cardiomyopathy represents the extreme phenotype, resulting 
in demise before the other clinical symptoms become evident. This observation further illustrates 
the role of ALMS1 and cell cycle regulation.  
KEYWORDS  
Cardiomyopathy, Alström syndrome, ALMS1, exome sequencing, ciliopathy 
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INTRODUCTION 
Cardiomyopathies are a heterogeneous group of  primary myocardial disorders in which the heart 
muscle is structurally and functionally abnormal, in the absence of other causes including coronary 
artery disease, hypertension, valvular or congenital heart disease [1].The annual incidence of 
pediatric cardiomyopathy is low, 1/100 000 children, with the highest incidence in the first year of 
life [2, 3]. Four major types are distinguished, i.e., dilated, hypertrophic, restrictive, and 
arrhythmogenic right ventricular cardiomyopathy [4]. Other unclassified types, which do not meet 
the criteria of one of the above, include endocardial fibroelastosis and ventricular non-
compaction.  
Mitogenic cardiomyopathy is an extremely rare type of dilated cardiomyopathy leading to death in 
early infancy. To date, only 6 cases have been reported in 4 families [5, 6]. Zerbini et al. described 
this condition in an 8-day-old infant, who died suddenly. Pathological examination revealed 
normal cardiac anatomy. The right ventricle was slightly dilated and endocardial fibroelastosis was 
present. Histology of the myocardium showed numerous mitoses and frequently enlarged 
myocardial nuclei with condensed chromatin forming a serrated thread running in the long axis, 
termed caterpillar nuclei. They observed an increased DNA ploidy of myocardial cells.  The 1-
month-old sibling of this patient also presented with heart failure and severe, dilated 
cardiomyopathy. An endomyocardial biopsy revealed endocardial fibroelastosis, but no increased 
mitoses. DNA ploidy analysis, on the other hand, showed an increased ploidy of the myocardial 
cells.  This patient responded positively to intensive treatment; however, no long term follow-up 
data are available. In 2010 Chang et al. described 5 cases with an identical disorder, including 2 
pairs of siblings. They all presented during early infancy with symptoms of cardiac failure and died 
soon thereafter. There were no associated extracardiac anomalies. Autopsy showed an enlarged, 
dilated heart, mostly ventricular, with endocardial fibroelastosis in all cases. Distinct findings were 
nuclear hypertrophy of the cardiomyocytes and a markedly increased mitotic activity with a 
proliferative index of 10 to 20% (normal < 1%), as well as caterpillar nuclei. In 1 of the 2 pairs of 
siblings there was parental consanguinity. This, and the observation of affected males and females 
strongly suggested autosomal recessive inheritance. We here report a novel family with an 
identical disorder. By a combination of linkage analysis and exome sequencing, we identify 
mutations in the ALMS1 gene as the cause of this distinct type of cardiomyopathy.  
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PATIENT DATA 
Patient 1  
The index is the second child of healthy, consanguineous parents of Turkish descent. He was born 
at 41 weeks of gestation after an uneventful pregnancy. Weight was 3200g (3rd-10th centile). He 
presented at age 20 days with excessive crying and feeding difficulties. On clinical examination, an 
inguinal hernia was noted. On reducing the hernia, cardio-circulatory arrest occurred. He was 
resuscitated and transferred to the university hospital. Despite continuous and prolonged 
resuscitation, the infant demised. Postmortem echocardiography revealed a structurally normal 
heart.  
The child was not dysmorphic. Weight was 4180 g (50th centile), length 56,5 cm (75th-90th centile) 
and head circumference 37,5 cm (50th centile). Pathological examination revealed signs of 
congestive cardiac failure (Figure 1). The weight of the heart was 31,1g (75th-95th centile) which is 
within normal range for age[7]. There was cardiomegaly, caused by globular dilatation of the left 
ventricle [8]. The endocardium was pale and thickened, indicative of endocardial fibroelastosis, 
which was confirmed histologically.  Apart from this “dilated cardiomyopathy”, the heart was 
structurally normal, including normal origin of the coronary arteries and normal aortic and mitral 
valves. There were no signs of non-compaction cardiomyopathy. Histology showed no signs of 
myocarditis, nor was there any evidence for a metabolic disorder. Myofibrillar disarray was 
absent. The most striking phenomenon was a marked mitotic activity in the cardiac myocytes 
(Figure 2). The myocardium also showed myocyte nuclear hypertrophy with the frequent 
occurrence of binuclear and even trinuclear myocytes. Some myocytes contained caterpillar nuclei 
(Figure 3), thus named due to condensed chromatin forming a serrated thread in the long axis. 
Immunohistochemical staining for Ki-67 (Mib1) showed a markedly increased proliferative activity 
of the myocardium. The proliferation index was 20% (normal value <1%). These findings lead to 
the diagnosis of mitogenic cardiomyopathy. 
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Left ventricular dilatation 
 
Figure 1. This specimen (patient 1) of the left ventricle clearly shows left ventricular dilatation and 
endocardial fibroelastosis. The heart was structurally normal. 
Increased myocardial proliferation 
 
Figure 2. This image shows markedly increased proliferative activity of the myocardium. 
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Caterpillar nuclei 
 
Figure 3. Caterpillar nuclei with condensed chromatin 
 
Patient 2 
Because of the high recurrence risk, the following pregnancy was closely followed. Repeated 
prenatal cardiac ultrasound investigations remained normal. A female infant was born at 41 weeks 
gestation, weighing 2840 g (3rd-10th centile). Early neonatal echocardiography was normal. 
However, at day 19, she was admitted with overt heart failure. Echocardiography (figure 4) 
revealed a dilated cardiomyopathy with left ventricular inner dimension at end-diastolic (LVIDd) of 
25mm (normal 12.9-19.1mm) [8]. There was endocardial fibroelastosis and severe mitral and 
tricuspid regurgitation. Cardiac function was poor, with a fractional shortening (FS) of 12% (normal 
≥30%) and retrograde pulmonary hypertension. Despite respiratory and circulatory support, she 
progressively deteriorated and demised at the age of 22 days. No autopsy was performed.   
Family history was otherwise negative; cardiac investigations of both parents and the 5 year old 
sibling were normal (figure 4). Informed consent was given by the family for further genetic 
studies. 
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Echocardiography 
 
Figure 4. Echocardiography using M-mode showing poor cardiac function (FS 12%, normal >30%) 
and dilated left ventricle. Left ventricle posterior wall at end- diastole (LVPWd), left ventricle inner 
dimension at end-diastole (LVIDd), Interventricular septum at end-diastole (IVSd), Left ventricular 
fractional shortening (FS). 
 
METHODS 
Linkage analysis 
Genomewide parametric linkage analysis with Merlin software was performed [9]. A dense SNP 
marker set derived from the 250k Affymetrics SNP typing platform was used in a recessive model. 
Genotyping was done on DNA extracted from peripheral white blood cells, obtained from the 
parents and both the unaffected and affected siblings.  
 
Exome analysis 
Library construction for all samples were prepared using TruSeq DNA Library Preparation Kit 
(Illumina, Inc., San Diego, CA, USA) in which platform-specific adaptors and unique DNA indexes 
were ligated. For each sample, 1 µg genomic DNA was sheared by sonication to approximately 
300bp fragments, followed by end-repair, adenylation and adapter ligation steps. DNA sequencing 
libraries were subsequently enriched with the SeqCap EZ Human Exome Library v3.0 (Roche, 
NimbleGen), and 2 × 100-bp paired-end reads were generated on the Illumina HiSeq2000 platform  
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with 3-4 exome-seq samples pooled per lane of a sequencing flow-cell.  Sheared DNA, whole 
genome libraries and enriched exome-seq libraries were validated using DNA-1000 chips on the 
BioAnalyser (Agilent), and library concentrations were determined using the dsDNA Broad Range 
Assay using the Qubit (Invitrogen). 
Data analysis was done using commercial and in-house developed software (Genomics Core/UZ 
Leuven). Exome sequences were obtained from both parents, patient 1 and the unaffected sister.  
Filtering was done with a High-quality depth of 5. From the variant files, we only retained variants 
in genes from the linkage regions. Additional mutations in all known hypertrophic and dilated 
cardiomyopathy genes were excluded. All homozygous calls were excluded in the parents and the 
unaffected sibling, reference calls were excluded in the affected sibling. According to Ensembl 
(www.ensembl.org) only exonic and splicing variants were included. Synonymous variants were 
excluded. Variants occurring with a frequency of <1% in the 1000 genomes project or with an 
unknown frequency were included. All remaining calls were checked for correct calling using 
Integrative Genomics Viewer (IGV, Broad Institute, Cambridge, MA, USA). 
RESULTS 
Linkage analysis 
In 8 regions the maximum LOD score of 1.9 was reached. All together these regions were spanning 
76, 769 163 Mb and contained 487 Human Genome Organization (HUGO) genes.  
 
Exome sequencing 
After variant filtering as outlined in the methods section, we identified 6 candidate genes in the 
linkage region with homozygous mutations in the patient, inherited from both parents, and for 
which the unaffected sibling is heterozygous or reference (supplementary table 1S). This gene list 
was manually curated using functional data and genotype-phenotype correlations for the 
implicated genes. We thus identified a deleterious mutation in the ALMS1 gene as the most likely 
cause. No additional mutations were found in known hypertrophic or dilated cardiomyopathy 
genes. 
Results were confirmed by Sanger sequencing (Figure 2S). The two affected siblings are 
homozygous for a frameshift deletion of one basepair in the ALMS1 gene 
NM_015120.4:c.7760delG, p.Cys2587Phefs*5 (NC_000002.11:g.73716849delG or 
NG_011690.1:g.108964del). This is predicted to cause a premature stop at position 5 downstream. 
The unaffected sister and parents are heterozygotes. 
99 
 
DISCUSSION 
We report a novel family with an extremely rare and lethal disorder: mitogenic cardiomyopathy. It 
is characterized by infantile-onset dilated cardiomyopathy resulting in irreversible heart failure 
and death. Histologically, there is a dramatically increased mitotic activity in the cardiomyocytes. 
Given the likely autosomal recessive inheritance and parental consanguinity in this family, the 
combination of linkage analysis and exome sequencing allowed us to identify mutations in the 
ALMS1 gene as the most likely cause of the condition in this family. The homozygous mutation in 
ALMS1 was located in a 3, 435 478 MB region on chromosome 2 (Supplemental figure 1S).  
The cardiac phenotype of dilated cardiomyopathy, although more severe, fits with Alström 
syndrome. In Alström syndrome, more than 60% of individuals develop congestive heart failure, 
most often dilated cardiomyopathy. An episode of heart failure due to dilated cardiomyopathy 
occurs in about 40% of cases during early infancy, between 2 and 16 weeks of age [10]. In most 
cases the initial poor cardiac function improves and patients remain stable for many years. In 
about 15% a recurrence of restrictive heart failure occurs during adolescence or adulthood. In 
addition, 20% of patients present in adolescence or adulthood with progressive restrictive 
cardiomyopathy.  Besides this interfamilial variability, pronounced intra-familial variability has 
been observed regarding the occurrence and severity of  cardiomyopathy [11]. Thus, the severe 
dilated cardiomyopathy observed in the present family can be regarded as an extreme 
presentation of Alström syndrome. The clinical presentation in these infants is dominated by heart 
failure, at an age when the additional manifestations such as nystagmus were not yet evident. For 
this reason, the diagnosis of Alström was not suspected. It is currently not known whether 
mitogenic cardiomyopathy is a feature of Alström syndrome related to dilated cardiomyopathy 
during infancy. We were unable to find reports or pathological data in infants with proven Alström 
syndrome. Also, we currently do not know whether the other cases with mitogenic 
cardiomyopathy are also caused by mutations in ALMS1. No biological material could be obtained 
from the previously reported cases.  
There is no immediate explanation for the more severe phenotype observed in this family. On the 
one hand, this may be due to ascertainment bias.  On the other hand, the marked intra-familial 
variability, and interfamilial variability observed in individuals sharing the same ALMS1 mutations 
suggests the presence of genetic and/or environmental modifiers [12]. The mutation occurs in a 
region where many other mutations have been reported before, and, similarly to most of them 
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result in a (predicted) truncated protein [13]. Additional mutations in known hypertrophic or 
dilated cardiomyopathy genes were excluded. 
The present observation indicates a link between ALMS1 and the mechanisms underlying the 
neonatal structural and functional changes in the heart. In the different developmental stages 
from fetus to adult, the ventricular myocardium differs morphologically, quantitatively and 
qualitatively in function and structure. In the adult myocardium the myocytes are organized in 
parallel and there is little interstitial tissue between myocytes. Polyploidy is frequently noted and 
the nucleus is relatively small. In the fetal heart, myocytes are less well organized and the 
intercellular space is greater. Nuclei are large and polyploidy is unusual. In the immediate weeks 
following birth, a rapid decrease in myocyte mitosis is noted; essentially all growth beyond the 
early neonatal period is due to hypertrophy. The stimulus is the normal developmental increase in 
mural stress and work. The workload of the left ventricle increases postnatally due to increased 
left ventricular output. This causes a rapid increase in thickness and weight of the left ventricle 
due to an increase in myocytes [14, 15]. 
The increased mitotic activity observed in cardiomyocytes in the present condition suggests a 
defect in cell cycle regulation. ALMS1 localizes to centrosome and to the ciliary basal bodies. There 
is a well-established role of the primary cilium in regulating cell cycle [16]. Of interest, in a mouse 
model for Alström syndrome, carrying a homozygous truncating mutation in exon 10 (alms1 
L2131X/L2131X), [17] loss of cilia in the kidney was observed in older mice, associated with increased 
proliferation and cyst formation as well as apoptosis. In these mice, no cardiac phenotype was 
described. Also in the heart, cilia may play a role in cardiomyocyte development and proliferation.  
Abolishing the function of the primary cilium in the pluripotent mouse stem cells P19.CL6 prevents 
further differentiation of these cells into beating cardiomyocytes [18].  
Reaching a genetic diagnosis in rare disorders remains a challenge. We illustrate that even in a 
single family with only two affected individuals, the identification of the underlying defect is 
feasible, using a combination of the sophisticated genetic tools. As in this family, we anticipate 
that the unbiased whole exome screens for mutation is likely to reveal further phenotypic 
heterogeneity in previously well delineated monogenic conditions.  
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SUPPLEMENTAL MATERIAL 
Linkage region 
 
Figure 1S. Linkage region in chromosome 2. 
  
105 
 
Sanger sequencing 
 
Figure 2S. Sanger sequencing results showing a homozygous deletion of one basepair in the 
ALMS1 gene in the two affected siblings (3, 4). The parents are heterozygous (1, 2). 
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ABSTRACT 
Aims 
Congenital or neonatal cardiomyopathies are commonly associated with a poor prognosis and 
have multiple etiologies. In two siblings, a male and female, we identified an undescribed type 
of lethal congenital restrictive cardiomyopathy affecting the right ventricle. We hypothesized 
a novel autosomal recessive condition. To identify the cause, we performed genetic, in vitro 
and in vivo studies.  
 
Methods and Results 
Genome-wide SNP typing and parametric linkage analysis was done in a recessive model to 
identify candidate regions. Exome sequencing analysis was done in unaffected and affected 
siblings. In the linkage regions, we selected candidate genes that harbor two rare variants with 
predicted functional effects in the patients and for which the unaffected sibling is either 
heterozygous or homozygous reference. We identified two compound heterozygous variants 
in KIF20A; a maternal missense variant (c.544C>T: p.R182W) and a paternal frameshift 
mutation (c.1905delT: p.S635Tfs*15). Functional studies confirmed that the R182W mutation 
creates an ATPase defective form of KIF20A which is not able to support efficient transport of 
Aurora B as part of the chromosomal passenger complex. Due to this Aurora B remains 
trapped on chromatin in dividing cells and fails to translocate to the spindle midzone during 
cytokinesis. Translational blocking of KIF20A in a zebrafish model resulted in a cardiomyopathy 
phenotype. 
 
Conclusion 
We identified a novel autosomal recessive congenital restrictive cardiomyopathy, caused by a 
near complete loss-of-function of KIF20A. This finding further illustrates the relationship of 
cytokinesis and congenital cardiomyopathy.  
 
Keywords 
Congenital cardiomyopathy, KIF20A, cytokinesis, exome sequencing, linkage analysis 
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INTRODUCTION 
Cardiomyopathies are a heterogeneous group of primary myocardial disorders in which the 
heart muscle is structurally and functionally abnormal, in the absence of other causes such as 
coronary artery disease, hypertension, valvular or congenital heart disease [1]. The annual 
incidence of paediatric cardiomyopathy is low, 1/100 000 children, with the highest incidence 
in the first year of life [2, 3].  
Congenital or neonatal cardiomyopathies are commonly associated with a poor prognosis and 
have multiple etiologies. These etiologies differ considerably from cardiomyopathies in older 
children and adults[4]. Congenital cardiomyopathies can be divided into different groups 
according to the clinical presentation and echocardiographic criteria: hypertrophic (HCM), 
dilated (DCM), restrictive (RCM), or unclassified including ventricular non-compaction 
cardiomyopathy and endocardial fibroelastosis. Genetically, most cardiomyopathies are 
caused by pathogenic mutations in genes coding for sarcomeric proteins [5, 6].  
The etiological landscape in congenital hypertrophic cardiomyopathy is heterogeneous; 
including various cellular mechanisms such as storage of metabolites as in Pompe disease, 
disturbed energy metabolism (e.g. fatty acid oxidation defects and mitochondrial diseases), 
altered signal transduction pathways (e.g. rasopathies due to mutations in genes altering the 
Ras subfamily and mitogen-activated protein kinases as in Noonan syndrome) or altered cell 
proliferation (e.g. as in Beckwith-Wiedemann syndrome).  Congenital dilated cardiomyopathy 
is most frequently caused by myocarditis, but mitochondrial diseases can also present as DCM.  
Restrictive cardiomyopathy (RCM) is very rare and mostly affects older people. It accounts for 
2.5-5% of all diagnosed cardiomyopathies in children and occurs in less than 1 per million 
children. It is characterized by the replacement of normal heart muscle by abnormal tissue, 
such as scar tissue which makes the ventricles become stiff and rigid [7, 8]. The systolic 
function is usually normal, but the diastolic function and relaxation of the ventricles are 
abnormal. The stiff ventricles do not allow the atria to empty normally, resulting in dilated 
atria and signs of heart failure. Often, there can be a lack of symptoms which makes the 
diagnosis difficult. Therapeutic options are limited resulting in a high morbidity and mortality. 
Several systemic and myocardial diseases, e.g. amyloidosis, metabolic diseases, sarcoidosis 
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and scleroderma, are associated with RCM; but idiopathic RCM remains the most common 
[9].  
We report a small family with an undescribed type of congenital cardiomyopathy resulting in 
a lethal restrictive cardiomyopathy. Clinical, genetic and functional studies were performed 
which led to the identification of a near complete loss-of-function of KIF20A as the most likely 
cause of this disorder. 
 
CLINICAL DESCRIPTION 
We present a small Caucasian family with three children (Figure S1). The parents are not 
consanguineous. Two of the children, one male (II-2) and one female (II-3), were diagnosed in 
late fetal life with a congenital heart defect categorized as restrictive cardiomyopathy of the 
right ventricle (RV). In the male index patient, the diagnosis of a small RV with severe 
pulmonary stenosis was made at the postmenstrual age (PMA) of 35 weeks. Due to secondary 
hydrops foetalis, with chylothorax and ascites, labour was induced at 35 weeks and 2 days. At 
birth, weight was 2400g (25th-50th centile), length 48cm (75th centile) and head circumference 
31,8cm (25th-50th centile). Postnatal echocardiography (Figure 1) confirmed the diagnosis of a 
bipartite RV with agenesis of the apex, a functional pulmonary stenosis, moderate pulmonary 
insufficiency (grade 2/4) and severe tricuspid insufficiency (grade 3/4). Due to a pulmonary 
circulation dependent on a patent ductus arteriosus, IV prostaglandin was started. On day 1 
percutaneous dilatation of the pulmonary valve was performed and the ductus arteriosus was 
stented. On day 5 a Rashkind balloon septostomy of the intra-atrial septum was performed. 
Due to persistent ascites, pronounced hepatomegaly and increased transaminases, an MRI of 
the liver and liver biopsy was performed at 40 days postnatal age. This showed 
billirubinostasis, hypoplasia of the portal veins and associated hyperplasia of the portal 
arteries. A preliminary diagnosis of a ductal plate abnormality was made. During the 
subsequent weeks, the heart function of both ventricles progressively decreased. At the age 
of 3 months the decision was made to start palliative care and the patient demised at the age 
of 93 days. Autopsy confirmed the cardiac diagnosis. There was pronounced sub-endocardial 
to transmural ischemic fibrosis of the myocardium. The myocardial tissue was hypertrophic 
with hydropic swelling and myocytolysis. The endocardium showed fibrous thickening. The 
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myocardium of the left ventricle (LV) was grossly normal, except for endocardial fibrosis which 
was clearly less pronounced compared to the RV. Pronounced chronic venous congestion of 
the liver was noted with cardiac fibrosis. The venous centrolobular walls were severely 
thickened with formation of centro-central fibrous septae. Ductal proliferation was present, 
but ductal plate malformation could not be confirmed given the normal central bilious ducts 
in the larger portal fields.  
 
In a following pregnancy, at the PMA of 32 weeks, the diagnosis of restrictive right ventricular 
cardiomyopathy with RV dysfunction was made in the female fetus. She was born at the PMA 
of 37 weeks. Her weight, length and head circumference at birth were within normal range; 
3,450 kg (25th-50th centile), 49,5cm (10th-25th centile) and 33,8 cm (3rd-10th centile) 
respectively. She was admitted in NICU due to cyanosis and cardiac decompensation with 
pronounced ascites. Postnatal echocardiography confirmed the diagnosis of a restrictive 
cardiomyopathy. The pulmonary valve was morphologically normal, but decreased 
anterograde flow as well as moderate tricuspid insufficiency was present (grade 2/4) 
secondary to RV dysfunction. No hepatic abnormalities were present. In the following weeks 
the heart function progressively decreased, at the age of 71 days (2 months) the patient 
demised. An autopsy was not performed.  
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Figure 1. Echocardiography of index patient 
Postnatal echocardiography of patient II-2 showing a bipartite RV with agenesis of the apex. 
Marked dilatation of the RA due to severe tricuspid insufficiency (grade 3/4). RA, right atrium; 
RV, right ventricle; LV, left ventricle; LA, left atrium. 
 
METHODS 
Linkage Analysis  
Genotyping was done on DNA extracted from peripheral white blood cells, obtained from the 
parents and both the unaffected and affected siblings. A dense SNP marker set derived from 
the 250k Affymetrics SNP typing platform was used in a recessive model. Genome wide 
parametric linkage analysis with Merlin software was performed 
(http://www.sph.umich.edu/csg/abecasis/Merlin/tour/parametric.html). 
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Whole Exome Sequencing  
Whole exome sequencing was done on both patients and the unaffected sibling. Genomic 
DNA was sheared by sonication, platform-specific adaptors were ligated, and the resulting 
fragments were size selected. The library was captured using the SeqCap EZ Human Exome 
Library v2.0 (Roche NimbleGen®), and 2 x 76 bp paired-end reads were generated on a 
HiSeq2000 (Illumina®). Reads that did not pass Illumina’s standard filters were removed prior 
to alignment. Remaining reads were aligned to the reference human genome (hg19), using 
the Genome Analysis ToolKit (GATK) pipeline. After duplicate removal, local realignment and 
base quality score recalibration, the data were used for variant calling with GATK Unified 
Genotyper (2.4-9). Annovar was used for functional annotation of detected variants. Quality 
filtering was applied by excluding variants found in less than 5 reads and variants detected in 
less than 15% variant reads.  
 
From the variant files, we only retained variants in genes from the linkage regions. Exonic 
variants and only intronic variants located less than 6 bp from the intron-exon boundary were 
included. Synonymous variants were excluded. Variants occurring with a frequency of <1% in 
the 1000 genomes project or with an unknown frequency were included. Variant filtering was 
done under the hypothesis of autosomal recessive inheritance, thus retaining only 
homozygous or compound heterozygous variants in both affected siblings, but not in the 
unaffected sibling. All remaining calls were checked for correct calling using Integrative 
Genomics Viewer (IGV, Broad Institute, Cambridge, MA, USA). 
 
Real-Time Quantitative PCR  
Primary fibroblasts from patients and unrelated controls were grown from skin biopsy and 
cultured in Dulbecco’s modified Eagle medium DMEM/F12 (Life Technologies®) supplemented 
with 10% fetal bovine serum (Clone III, HyClones), 1% streptomycine and 0,02% Fungizone at 
37°C under 5% CO2.  
The PCR was performed for KIF20A (GenBank NM_005733) and the house-keeping gene 
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase, GenBank NM_002046), which was used 
as an endogenous control for normalization. qPCR primers were designed using Genscript 
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software (www.genscript.com/ssl-bin/app/primer). All primers were synthetized by 
Integrated DNA Technologies. 
 
Reagents and antibodies 
General laboratory chemicals and reagents were obtained from Sigma-Aldrich and Thermo 
Fisher Scientific. Sheep antibodies were raised to the KIF20A motor domain (N) or neck plus 
C-terminus (C) domains. Rabbit antibodies to KIF4A, KIF23, PRC1 and KIF23 pS911 peptide 
were described previously [10-13]. Specific antibodies were purified using the antigens 
conjugated to Affi-Gel 15, eluted with 0.2 M glycine-HCl, pH 2.8, and then dialyzed against PBS 
before storage at −80°C. Commercially available antibodies were used to AIM1 (mouse 
611083; BD). Affinity-purified primary and secondary antibodies were used at a final 
concentration of 1 µg/ml. Secondary antibodies conjugated to Horseradish Peroxidase (HRP) 
were obtained from Jackson ImmunoResearch Laboratories, Inc. Secondary antibodies for 
microscopy conjugated to Alexa Fluor 488, 555, and 647 were obtained from Invitrogen. DNA 
was stained with DAPI (Sigma-Aldrich). 
 
Molecular biology 
Human KIF20A was amplified directly from human testis cDNA. The KIF20A R182W mutant 
was created using QuikChange mutagenesis according to the instructions from Agilent 
Technologies. Mammalian expression constructs for N-terminally GFP-tagged KIF20A was 
made using pcDNA5/FRT/TO vector (Invitrogen). Hexahistidine-tagged bacterial expression 
constructs for the motor domain (1-507) of wild type KIF20A or R187W KIF20A were made in 
pQE32 (QIAGEN). 
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Cell culture and microscopy 
HeLa cells were cultured in DMEM containing 10% (vol/vol) bovine calf serum (Invitrogen) at 
37°C and 5% CO2. For synchronization, cells were treated for 18 hours with 2mM thymidine, 
washed three times in PBS, and twice with growth medium. For plasmid transfection and 
siRNA transfection Mirus LT1 (Mirus Bio LLC) and Oligofectamine (Invitrogen) were 
respectively used. The siRNA duplexes used targeted the following sequences: control 5′-
CGTACGCGGAATACTTCGA-3′, KIF20A 3’-UTR 5′-CCACCTATGTAATCTCATG-3′. Microscopy was 
performed as described previously[13]. 
 
Protein expression and purification 
The motor domains of KIF20A wild type and R187W were expressed in Escherichia coli strain 
JM109 and purified after induction for 3 hours with 0.5mM IPTG. Cell pellets were washed 
once in ice-cold PBS, and then lysed in 20 ml of IMAC20 (20mM Tris-HCl, pH 8.0, 300mM NaCl, 
20mM imidazole) and protease inhibitor cocktail (Sigma-Aldrich) for 20 minutes on ice. Cell 
lysis was performed using an Emulsifex C5 cell breaker system (Avestin Europe GmbH). Cell 
lysate was clarified by centrifugation and loaded onto a 1-ml HisTrap FF column (GE 
Healthcare) at 0.5 ml/min. The column was then washed with 30 ml of IMAC20, and eluted 
with a 20-ml linear gradient from 20 to 200mM imidazole in IMAC20 collecting 1 ml fractions. 
Peak fractions were buffer exchanged using 5 ml Zeba Desalt Spin columns (Perbio) into TND 
(20mM Tris-HCl, pH 8, 300mM NaCl, and 1mM DTT). Protein samples were snap-frozen in 15-
µl aliquots and stored at −80°C for further use. 
 
Kinesin motor ATPase assays 
A commercial enzyme–linked inorganic phosphate assay was used to measure kinesin ATPase 
activity (Cytoskeleton, Inc.) as described previously[13]. In brief, a microtubule premix was 
created at room temperature by mixing 1ml of reaction buffer (15mM PIPES-KOH pH 7 and 
5mM MgCl2), 10µl of 2mM paclitaxel, 80µl of preassembled microtubules (1mg/ml tubulin, 
15mM PIPES-KOH pH 7, 5mM MgCl2, 1mM GTP, and 20µM paclitaxel), 240µl of 1mM 2-amino-
6-mercapto-7-methylpurine riboside, and 12µl of 0.1U/µl purine nucleoside phosphorylase. 
Reactions were set up in 96-well plates by mixing the protein of interest in a total volume of 
7.5µl TND with 147.5µl of the microtubule premix at room temperature. To start the assay, 
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10µl of 10mM ATP was added to each well. Final assay volume was 165µl of 12mM PIPES-KOH 
pH 7, 4mM MgCl2, 0.61mM ATP, and 14.5mM NaCl. This was then rapidly transferred to a 37°C 
plate reader (Tristar LB 941; Berthold Technologies) set to read absorbance at 360nm. 
Readings were acquired every 30 seconds during 1 hour. An inorganic phosphate standard 
curve was created in the same assay buffer and used to convert absorbance to nmol 
hydrolysed ATP. 
 
Zebrafish model 
A. Zebrafish maintenance and transgenic lines.   
Wild-type, Tg(kdrl:EGFP)s843  and double transgenic Tg(gata1:DsRed2;kdrl:EGFP) zebrafish 
lines were maintained as previously described[14]. Embryos were collected by natural matings 
of zebrafish adults and incubated in egg water at 28.5°C according to The Zebrafish Book. 
Embryos at different developmental stages were presented as hours post fertilization (hpf) or 
days post fertilization (dpf)[15]. 
 
B. Antisense morpholino oligonucleotides and zebrafish embryo microinjection.  
The translational blocking morpholino oligomer (MO) for zebrafish kif20a was designed and 
ordered from Gene-Tools, LLC (OR, USA). Its sequence is 5’-
GCATGGAGACGCCAGAGCCATTATA-3’. Lyophilized MOs were diluted in water according to the 
protocol of Gene Tools. Stocks were further diluted to different working concentrations with 
phenol red added as indicator. 15 ng kif20a-MO was injected into 1-2 cell stage embryos.  Co-
injection of p53 MO was performed to rule out a possible toxicity of MO off-target effect. The 
dose dependent effect of kif20a morpholino was performed by injection of different 
concentrations of MO into 1-2 cell stage embryos. The efficiency of MO on inhibiting kif20a 
expression was checked by Western blot assay. The antibody for human KIF20A protein was 
home-made by immunizing sheep and purified. The proteins were extracted from 48 hpf 
embryos in RIPA buffer (Thermo Scientific, USA) with protease inhibitor (Roche, Germany). 
The same amount of protein samples were loaded in the Bis-Tris 4–12% SDS-PAGE denaturing 
gel (The sequence of antigen will be provided upon request.).  
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For the rescue experiment embryos were injected with kif20a-MO together with 10 pg 
pcDNA3.1 plasmids carrying either a human KIF20A WT cDNA or KIF20A R182W cDNA 
fragment. Cardiac phenotypes were analyzed at 3dpf.  
C. Imaging and data analysis. 
Live embryos were photographed with a Nikon SMZ18 microscope. Confocal images of live 
embryos embedded in 0.9% low melting agarose were made with a Nikon Spinning-Disk 
confocal microscope, images were generated by ImageJ software. 
 
D. Zebrafish embryonic cardiac function evaluation. 
Live confocal imaging was done to quantify cardiac function using a Nikon Spinning-Disk 
confocal microscope. Five to nine embryos of WT and kif20a-atgMO respectively were imaged 
at 72 hpf (day 3) and 96 hpf (day 4). This was repeated totaling 54 zebrafish larvae, respectively 
28 WT and 26 kif20a-atgMO. The atrium and ventricle was imaged separately, images were 
processed by ImageJ software. Heart rate was calculated by counting the number of beats in 
15 seconds and multiplying by 4 to obtain beats per minute. Fractional shortening (%) was 
calculated using the formula (100)(width at diastole–width at systole)/(width at diastole) for 
the atrium and ventricle as described before by Hoage et al[16]. Statistical analysis was done 
using SPSS software. P-values were calculated using Mann-Whitney U test, the significance 
threshold was set at .001. 
E. Histology 
Embryos at 4dpf were stored in 4% PFA in PBS and transferred to warm DEPC treated saline 
on a heating plate. Sequential transfer of embryos from the saline through the increasing 
agarose concentrations (0.25% - 1.5%) was done every 10 seconds on a heating plate of 60°C. 
The final 1.5% agarose is cooled to room temperature after positioning and orientation of the 
embryos. Agarose is dehydrated in 70% EtOH/saline while kept on ice. Samples are imbedded 
in paraffin after graded dehydration in methanol. Transverse sections of 4µM were made 
using wet mounting with a RN2255 microtome (Leica Technology). Staining was done with 
Harris hematoxylin and special eosin II (BBC Biochemical, Mount Vernon, WA, USA), the 
stained sections were imaged with a Motic AE31 TrinocularAE30 Inverted Microscopeswith 
Leica MC170 HD camera. 
118 
 
RESULTS 
Linkage analysis 
Linkage analysis was performed on the entire family, and maximal LOD-score (MLS) of 0,727 
was obtained in 27 regions (Figure S2). These regions contained a total of 1273 genes, 
obtained from Ensemble (www.ensembl.org).  
 
Whole exome sequencing and gene identification  
Whole exome sequencing was performed on both affected siblings and the unaffected sibling. 
After filtering the variants in the genes in the linkage regions, under a hypothesis of autosomal 
recessive inheritance, we identified 1 gene with a homozygous variant (PHCDA9) and 2 genes 
(ZNF587 and KIF20A) with compound heterozygous variants (Table 1S). The PCHDA9 gene 
contained a nonsynonymous variant (c.1006C>G: p.L336V) which was absent in the 1000 
genomes, but with an allele frequency of 51% in local exomes and common in the ExAC 
database. In ZNF587 two missense variants were detected, c.956C>G (p.T319S) and 
c.1676G>A (p.R559Q) with an allele frequency of respectively 1% and 6% in local exomes.  
 
In KIF20A we identified a missense variant (c.544C>T: p.R182W), changing an arginine to a 
tryptophan, and a frameshift mutation, creating a premature stop codon (c.1905delT: 
p.S635Tfs*15). The c.544C>T substitution in exon 6 results in a single amino acid substitution 
(p.R182W) within the motor domain of the protein. Arginine and tryptophan are members of 
different chemical amino acid groups, and the R182 amino acid is highly conserved across 
mammalian species. The variant c.544C>T: p.R182W was predicted to be damaging by in silico 
tools SIFT, Polyphen and MutationTaster. The c.1905delT in exon 15 results in a frameshift 
that introduces a premature stop codon 15 amino acids downstream. These observations 
suggest that both variants are likely to affect protein function.  
These variants were absent in the population control exomes. In the ExAC Browser database, 
containing genetic data of 60 706 humans of various ethnicities, the missense variant was 
found in 2 individuals, respectively of South Asian and European origin. The frameshift variant 
was present in 32 individuals of African descent. All of the KIF20A variants in this database are 
heterozygous [17]. Sanger sequencing validated the presence of both variants in the affected 
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siblings and confirmed a heterozygous carrier status in both parents (maternal c.544C>T and 
paternal c.1905delT). Both variants were absent in the unaffected sibling. Mutations in other 
known cardiomyopathy genes were absent in the two affected siblings. 
 
Quantitative real-time PCR (qPCR) was used to investigate the effects of the KIF20A variants 
on its expression by comparing KIF20A cDNA-levels amplified from mRNA isolated from 
patient and control fibroblasts. Both patients had a significantly reduced expression level to 
40-60 % of control levels (Figure 2A).  To investigate the effect of the variants on KIF20A 
protein levels, immunoblotting was performed using unrelated controls and patient 
fibroblasts. Both affected individuals had a reduced amount of endogenous KIF20A protein 
compared to controls (Figure 2B). Antibodies for the N-terminal and C-terminal part of the 
protein gave identical results, indicating that the frameshift mutation leads to elimination of 
the transcript by nonsense-mediated mRNA decay.  
The localization of the remaining KIF20A in dividing patient fibroblasts (c.544C>T: p.R182W) 
was then examined. These cells have approximately half the levels of KIF20A when compared 
to control fibroblasts, but retain normal levels of other cell division proteins (Figure 2C). In 
control cells, KIF20A localizes to the spindle midzone in anaphase and telophase of dividing 
cells where it promotes recruitment of the Aurora B kinase (Figure 3A). In both patients KIF20A 
was aberrantly targeted to chromatin and failed to support translocation of Aurora B to the 
spindle midzone (Figure 3A).  
As a consequence of the inability to relocate Aurora B to the spindle midzone, Aurora B 
phosphorylation of a key anaphase central spindle protein KIF23 was reduced (Figure 3B, 
arrows).  
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Figure 2. KIF20A mutations affect Aurora B transport during cell division in patient 
fibroblasts.  
Figure 2A shows quantification of KIF20A transcript level in unrelated controls and patients by 
qPCR. KIF20A expression was normalized to the expression of the house-keeping gene GAPDH. 
** indicates p < 0,01. Figure 2B shows KIF20A levels in unrelated control and patient 
fibroblasts undergoing cell division. Figure 2C shows western blot analysis of KIF20A and other 
anaphase spindle protein levels in unrelated control and patient fibroblasts. 
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Figure 3. KIF20A mutations affect Aurora B transport during cell division in patient 
fibroblasts.  
Localization of KIF20A in control (C2) and two patient (P1 and P2) fibroblasts undergoing cell 
division. Cells were stained with antibodies for KIF20A, Aurora B and the Aurora B pS911 
phosphorylation site on KIF23 (marked with arrows). 
 
This failure to move from chromatin to the anaphase spindle microtubules suggested that the 
missense mutation (c.544C>T: p.R182W) perturbed the kinesin motor activity. This possibility 
was therefore tested using microtubule-stimulated ATPase assays. Purified wild type or 
R182W mutant KIF20A proteins were tested over a range of concentrations in microtubule-
stimulated ATPase assays. Plots of the initial rate of ATPase hydrolysis as a function of the 
concentration of motor domain show that the KIF20A R182W missense mutation has greatly 
reduced microtubule activated motor activity (Figure 4A). This reduction in ATPase activity is 
typical of kinesin “rigor” mutants, which can bind to microtubules but cannot dissociate or 
move along them. To further pursue this idea, a wild type KIF20A E245A “rigor” mutant and 
the missense mutation present in the patient cells R182W were transfected into HeLa cells 
where the endogenous copy of KIF20A was removed by siRNA. In the absence of any KIF20A, 
Aurora B is trapped on chromatin and is not present on the central spindle Figure 4B. 
Expression of wild type KIF20A rescues the transport of Aurora B to the central spindle. 
However, neither the patient R182W mutation nor the rigor E245A supported efficient Aurora 
B transport and this remains trapped on chromatin in dividing cells. Together these results 
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indicate that the missense variant (c.544C>T: p.R182W) is a near-complete loss-of-function 
mutation creating an ATPase defective form of KIF20A. 
 
Figure 4. Functional studies of the KIF20A R182W mutant. 
(A) Microtubule stimulated ATPase assays for control wild type (WT) and patient (R182W) 
KIF20A proteins revealed a near complete loss-of-function. (B) Localization of wild type KIF20A 
(WT) and an engineered “rigor” mutant (E245A) and the patient-associated R182W mutant in 
HeLa cells revealed that Aurora B remains trapped on chromatin and is not present on the 
central spindle. 
 
Zebrafish model 
Knockdown analysis 
The R182 amino acid was conserved in zebrafish and human. Amino acid sequence alignment 
of human KIF20A and the zebrafish kif20a protein showed a 46% identity and 64% similarity 
(Figure S3), suggesting that zebrafish kif20a may have similar function as the human ortholog. 
The gene was expressed in all early zebrafish stages from 1-2 cell to 6 dpf (Figure 5A). Using a 
kif20a-atgMO, a 74% reduction in protein production was obtained at 48hpf (Figure 5B). 
Zebrafish hearts started beating at the expected 24 hpf. At 48hpf, cerebral oedema was 
observed, as well as a smaller trunk shorter total body length. From 2dpf onward a progressive 
cardiac phenotype was seen in the morphants with pooling of red blood cells proximal to the 
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atrium, relative tachycardia and cardiac oedema (Figure 5C). At 144 hpf (day 6) the abnormal 
phenotype was present in 90% of the 80 embryos in 4 independent experiments (Figure 6). 
Co-injection of P53 MO to rule a possible toxicity effect did not influence the phenotype. A 
dose dependent effect of kif20a-MO was evident (Figure 5D). Partial rescue was obtained by 
cDNA bearing human KIF20A WT, confirming kif20a was the gene responsible for the cardiac 
phenotype (Figure 5E). No rescue was seen with the R182W mutant. Together these results 
indicate that kif20a was essential for zebrafish heart development, an evolutionally conserved 
function. 
 
Histology of the heart and cardiac function 
The whole heart of kif20a morphants was smaller and significant pericardial edema was 
evident in all transverse sections of the morphants when compared with controls (Figure 6A). 
The atrioventricular (AV) valve in morphants appeared morphologically normal, the bulbus 
arteriosus (BA) was smaller and the atrial and ventricular walls were thicker compared to 
controls. A clear looping defect was present in the kif20a morphants (Figure 6A), where the 
atrium was located laterally at the same lever of the ventricle as opposed to dorsally in 
controls. Pooling of blood was present anterior to the atrium of the morphants, suggesting a 
decreased function.  
To better characterize the heart phenotype in kif20a morphants, we evaluated several cardiac 
parameters including heart rate and fractional shortening (FS). At 3dpf the heart rates were 
similar in the controls and kif20a morphants. At 4dpf the morphants showed a significant 
increase in heart rate (p = 0.009, Figure 6B), most likely as a response to progressive heart 
failure and decreased stroke volume, since cardiac output equals heart rate x stroke volume. 
Although an increased ventricular fractional shortening was seen in the kif20a morphants 
compared to the controls (40.6 % ± 10.38 vs. 30.49% ± 4.91, p = 1,62774E-05); more outliers 
were observed in the kif20a morphants which suggested systolic failure following diastolic 
failure (Table 1 and Figure 6B). The end-systolic diameter (ESD) of the atrium in kif20a 
morphants was significantly smaller (p = 0.001); this is most likely due to increased force 
necessary to empty the atrium into a more rigid ventricle. These findings suggest that kif20a 
is required for normal heart function in zebrafish embryos. 
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Figure 5. Zebrafish kif20a knockdown studies.  
(A) RT-PCR analysis of zebrafish kif20a gene expression during early stages. Gapdh was used 
as a housekeeping gene. 
(B) Western blot analysis of whole lysates from control and kif20a morphants showing a 74 % 
protein reduction. Actin was used as a loading control. 
(C) Morphological analysis of zebrafish control and kif20a morphants at 3-4 dpf. 
Upper panel: Bright-field and fluorescence images of zebrafish control and kif20a morphants 
at 3 dpf. The white star indicates cerebral oedema.  
Lower panel: Bright-field and fluorescence images of zebrafish control and kif20a morphants 
at 4 dpf. The red arrows indicate cardiac oedema.  
(D) Rescue experiments where embryos were injected with kif20a-MO only, together with 
human KIF20A WT cDNA or KIF20A R182W cDNA. The percentage of cardiac phenotype in 
each groups at 3 dpf is presented.  
(E) Dose dependent effect of kif20a-MO with varying concentrations of kif20a-MO (range 0-
2 mM), injection dose was 4,6 nl. The percentage of cardiac phenotype at 3 dpf is shown.  
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Figure 6. Histology and cardiac function evaluation of zebrafish kif20a morphants. 
(A) H&E staining of zebrafish embryos injected with control MO and kif20a MO at 4 dpf, magnification 
of 10x and 40x. Arrows indicate cardiac oedema. Upper panel: Bright-field images of control and 
kif20a morphants at 4 dpf showing the section locations (1 and 2).  
Lower panel: H&E staining images of control and kif20a morphants at position 1 and 2.  
 (B)  Cardiac function analysis. 
Left panel: Heart rate in beats per minute is compared in control and kif20a morphants at 
3 dpf and 4 dpf. A significant increase in heart rate is observed in the morphants at 4 dpf, most 
likely due to progressive cardiac failure. 
Right panel: Fractional shortening is compared in control and kif20a morphants respectively 
in the atrium and ventricle. Although a significant increased fractional shortening is present in 
the morphants, more outliers are seen, suggesting systolic failure. 
 
DISCUSSION 
We report a family with two siblings presenting with a novel lethal congenital heart disease. 
It was characterized by fetal-onset restrictive cardiomyopathy predominantly affecting the 
right ventricle and leading to irreversible heart failure and early death. Given the occurrence 
of the same distinct phenotype in siblings of both sexes with unaffected parents, autosomal 
recessive inheritance was likely. This phenotype is unique and to our knowledge has not been 
reported in literature previously. After exclusion of mutations in known CM genes, linkage 
analysis and exome sequencing was performed to identify the genetic basis. We were able to 
identify functional variants in the KIF20A gene as the most likely cause. Two compound 
heterozygous variants were found; one variant was a missense mutation (c.544C>T: 
p.R182W), the other a frameshift mutation, creating a premature stop codon (c.1905delT: 
p.S635Tfs*15). There is no known phenotype of constitutional KIF20A mutations in humans. 
In mice, homozygosity is lethal in all pups at an early age of 3-4 weeks, but no phenotypic 
details have been reported [18]. In a zebrafish model we showed that translational blocking 
of the zebrafish kif20a gene resulted in a cardiomyopathy phenotype and that kif20a is 
required for proper heart patterning and function, suggesting KIF20A has an evolutionary 
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conserved function in heart development. Future studies using more specific genetic knockout 
models could provide additional valuable information about its function. 
Kinesin family member 20A (KIF20A), a.k.a. Mitotic kinesin-like protein 2 (MKLP2) or Rab6-
interacting protein (RAB6KIFL) is one of the kinesin-like proteins. These proteins are 
microtubule-associated motors that play important roles in intracellular transport and cell 
division [19]. It is required for chromosomal passenger complex-mediated cytokinesis and 
translocation of the chromosomal passenger complex (CPC) from the chromatin to the central 
spindle in metaphase, anaphase and telophase[20]. Functional studies in patient fibroblasts 
revealed reduced protein levels associated with deficient transport of the Aurora B and the 
CPC which remains trapped on chromatin in dividing cells. This was due to the missense 
variant causing a near complete loss-of-function of the ATPase function of KIF20A. It is not 
excluded that a complete loss-of-function is embryonically lethal, and that the minimal 
residual function of one allele in this family allowed survival beyond fetal life. 
KIF20A is highly expressed in cardiac myocytes, fetal liver and thymus; and to a lesser extent 
in fetal heart, kidney, spleen and lung. The crucial role of PLK1 in cardiomyocyte proliferation 
has been shown in zebrafish. This cardiomyopathy phenotype predominantly affected the 
right ventricle. Currently, it is not known why this occurs. It might be related to a different 
origin of the right ventricle which is formed by the second heart field, compared to the left 
ventricle which originates from the primary heart field. However, this might also be secondary 
to distinct differences in function of the fetal left and right heart. Unlike the adult circulation, 
in the fetus, the stroke volume of the fetal LV is not equal to the stroke volume of the RV as a 
result of intracardiac and extracardiac shunting. The RV receives around 65% of the venous 
return and the LV about 35% [21]. A cardiomyopathy affecting predominantly the RV could 
thus lead to significant morbidity and possible mortality during the fetal or early neonatal 
period. This could lead to early unexplained mortality and underreporting of this specific 
phenotype. Additional phenotypic features becoming apparent at a later age would also be 
difficult to detect. 
The specific link with the cell cycle and this cardiopathy in humans is still unclear. Previously 
we and others reported mutations in the ALMS1 gene as a cause of mitogenic 
cardiomyopathy. This links cardiomyopathy to ciliopathy and the cell cycle [22, 23]. These 
reports open a new mechanism for future research in cardiomyopathies and cytokinesis. 
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SUPPLEMENTAL MATERIAL 
 
Figure S1. Pedigree of the family. 
II-2 and II-3 were diagnosed with restrictive cardiomyopathy, patients demised at the age of 
6 and 3 months respectively.  The parents and older sibling have a normal phenotype. 
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Figure S2. Represents the LOD score in function of the chromosomal position in 
centimorgan (cM). 
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Figure S3. Amino acid sequence alignment of human and zebrafish KIF20A genes.  
HsKIF20A, human KIF20A gene and Drkif20a, zebrafish kif20a gene are shown in alignment. 
Black highlighting shows identical residues with the red star indicating the conserved R182 
residue in human and zebrafish.  
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CHAPTER 5  
GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
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1. GENE IDENTIFICATION IN CONGENITAL HEART DISEASE 
The general objective of this study was to contribute to understanding the genetics of 
congenital heart defects (CHD) and congenital cardiomyopathies. One way to make progress 
is to identify novel genes and mechanisms involved in congenital heart disease, through the 
study of well-selected patients and families. We applied state-of-the art genetic technologies 
to screen the genome for intragenic mutations in sporadic and familial forms of unique types 
of syndromic CHD or cardiomyopathies. 
In two families with suspected autosomal recessive inheritance of a highly distinct type of 
lethal cardiomyopathy, we identified the underlying genetic cause. In one family, with 
mitogenic cardiomyopathy, a homozygous mutation in the ALMS1 gene was identified [1], a 
gene previously associated to Alström disease, a multisystem disorder also featuring 
cardiomyopathy.  Shortly after submitting our observation, another group reported the same 
finding in other, unrelated families with mitogenic cardiomyopathy [2]. In a second family, 
with a thus far undescribed phenotype of restrictive cardiomyopathy of the right ventricle, 
compound heterozygous mutations in the KIF20A gene were identified. Extensive functional 
data provide strong support to a causative role of these mutations in the phenotype. However, 
definitive proof would require confirmation in a second family with the same phenotype. No 
such family has been identified so far, despite many calls for patients at different cardiology 
meetings and searches in the literature and genetic databases. 
The finding of a novel genetic explanation for specific phenotypes has an important impact on 
the families involved. In the first family with ALMS1 mutations, we were confident enough of 
a causal relationship between the mutations and the phenotype to offer prenatal diagnosis in 
a subsequent pregnancy. However, opinions differed amongst geneticists whether in the 
second family with the KIF20A mutations, the data are sufficiently certain to allow the use in 
prenatal diagnosis, if requested. 
However, these results are also interesting from a more fundamental point of view. These two 
genes have a role in cell cycle regulation, and for the first time link mutations involved in this 
process to congenital cardiomyopathies. This is not unexpected. Fetal cardiomyocytes are 
mitotically active, but soon after birth, cardiomyocytes rapidly lose their capacity to divide and 
they undergo terminal differentiation. The ALMS1 protein plays a central role in this process 
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of mitotic arrest. In humans, lack of functional ALMS1 results in a dilated cardiomyopathy 
characterized by increased mitotic activity. Increased cardiomyocyte proliferation is also 
observed in cultured mouse cardiomyocytes where the Alms1 mRNA has been knocked-down. 
Likewise, postnatally, increased cardiomyocyte proliferation is seen in homozygous Alms1 
knockout mice [2]. How this leads to dilated cardiomyopathy is currently not known.  
ALMS1 is spatially associated with key components of the mitotic machinery: during mitosis, 
it localizes at the centrosomal spindle poles and during late mitosis also at the cleavage furrow 
and the contractile ring [3]. KIF20A, as one of the kinesin-like proteins also has a key role in 
regulating mitosis [4], through intracellular transport and cell division [5]. It is required for the 
translocation of a key player, the chromosomal passenger complex, from the chromatin to the 
central spindle in metaphase, anaphase and telophase [6]. 
These insights will contribute to a better understanding of the cellular processes mediating 
the fetal to postnatal transition of the cardiomyocyte.  
Besides these cardiomyopathies, we also studied syndromic forms of structural heart defects, 
CHD. In the cardiology clinic, many patients with syndromic CHD remain without diagnosis. 
Over the last years the introduction of NGS has resulted in a spectacular increase in the 
number of new genes causing a wide variety of developmental disorders [7-10]. Recent 
studies indicate that persons with a syndromic type of CHD carry an excess of de novo 
mutations in other genes besides those already associated to CHD or ID [11]. This indicates 
that many genes still remain to be discovered in this field. In our (small) cohort of patients, we 
identified the MEIS2 gene as a novel gene associated with a syndromic form of CHD, 
associated with cleft palate and ID. Since then, a number of other reports have confirmed this 
finding [12-14]. Likewise, we observed for the first time that CHD may belong to the 
phenotypic spectrum of DYRK1A mutations. Since then, this has also been confirmed by other 
research groups [11]. 
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2. NGS: POSSIBILITIES AND LIMITATIONS 
A second aim of this study was to provide updated guidance for genetic testing in the 
congenital cardiology clinic, in view of the recent introduction of diagnostic NGS.  
Exome sequencing in families with a clear monogenic disorder often fails to identify the causal 
mutation, as we experienced in 5 of the sporadic patients investigated in a trio approach, but 
also in three of our five familial cases. This indicates that WES has its limitations, which can 
be both technical and biological. It is therefore crucial that clinicians are aware of the 
limitations of NGS as a diagnostic tool, including missed mutations, difficulties in variant 
classification and the importance of good clinical phenotyping. 
 
1. TECHNICAL ASPECTS 
1.1. Failure to detect intragenic mutations 
A first step in exome analysis is capture of the exons of all coding genes [15, 16]. 
The efficiency at which exons are captured and sequenced is not equally distributed, resulting 
in regions that are poorly covered, meaning that the number of reads at this locus is too low 
to allow a reliable calling of variants sequences. For instance, the first exon of many genes is 
GC-rich, and is often poorly covered. A good quality experiment is 80% of the target region 
being covered at 20X or higher [17], meaning that on average, 20% of all exons in the target 
region are not high-quality calls analysed.  
Different bioinformatics tools exist that identify variants in the sequences. However, the 
concordance between these different tools is low [17]. This implies that with any variant 
calling tool used, true variants will be missed, even though a variant is present in a sufficient 
number of reads. In particular, calling of indels (small insertions or deletions, with a size below 
1kb) is challenging.  
WGS is expected to give a more even coverage, since there is no capture nor any PCR 
amplification step which may introduce a  bias [18]. Thus, it has been proposed that WGS 
yields 5% extra exonic mutations compared to exome [19]. 
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In a trio approach (depending on the stringency of the filter) unequal coverage may result in 
some calls and thus candidate genes not being taken into consideration, e.g. when a 
maternally inherited variant is not sufficiently covered in the mother.  
 
1.2. Exome sequencing will miss certain classes of mutations 
1.2.1. Structural variations including deletion or duplication CNV’s (size >1 kb) cannot be  
detected reliably by exome sequencing [15]. However, bioinformatics tools are being 
developed and it is expected that WGS will overcome this limitation.  Balanced structural 
anomalies such as inversions or translocations cannot be detected by WES, but again, WGS 
offers the opportunity to detect these [20]. 
 
1.2.2. Epigenetic mutations 
Currently, this category of mutations fall within the group of imprinting disorders. For the vast 
majority of autosomal genes, expression occurs simultaneously from both alleles. In 
mammals, however, a small proportion (<1%) of genes are imprinted, meaning that gene 
expression occurs from only one allele, either maternal or paternal. This is mediated by 
epigenetic alterations of these genes. Amongst other mechanisms (deletion, point 
mutations), epigenetic changes, associated with altered methylation profiles, can result in a 
developmental disorders such as Beckwith-Wiedemann syndrome, Prader-Willi syndrome, or 
Angelman syndrome. The diagnosis of this class of disorders requires dedicated technologies 
targeted at analysing the methylation profile of the sequences involved.  
1.2.3. Uniparental disomy 
Uniparental disomy occurs when both homologous chromosomes are inherited from a single 
parent, and the other parent’s chromosome for that pair is missing. For most chromosomes, 
this is without consequence, but for a few chromosomes, it can result in a disorder when the 
chromosome harbours an imprinted gene. Also, when the region harbours a mutation in a 
gene for an autosomal recessive disorder, uniparental isodisomy (meaning that both 
chromosomes are identical) will result in a recessive disorder. In a trio analysis, UPD will 
readily be detected since in the region absence of alleles from one parent will be detected.    
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1.2.4. Mosaicism 
Mosaicism results when a mutation occurs post-zygotically, and is present only in a proportion 
of cells. The first challenge is to detect a low grade somatic mosaicism, meaning that the 
variant is only present in a small proportion of cells and thus of the obtained sequences. This 
requires a much deeper sequencing, many more reads need to be obtained (with increasing 
cost) [21]. Second, the mutation may only occur in certain tissues, and thus escape detection 
in white blood cells. This has been observed for certain cortical dysplasias [22] and for Proteus 
syndrome [23]. 
1.2.5. Non-coding regions 
In some cases with a well-defined genetic condition no mutations can be detected in the 
coding parts of the gene causing this disorder. It is assumed that mutations in non-coding 
regulatory sequences can result in the disorder as well. To date, only very few examples exist, 
probably because it is still challenging to identify such mutations. Examples of mutations in 
non-coding sequencing resulting in a distinct phenotype include the SOX9 gene and Robin 
sequence [24], Cooks syndrome [25], and possibly also CHD [26],  the FOXL2 gene and BPES 
[27], the SHH gene in polydactyly [28], and the IRF6 gene and Van der Woude syndrome [29].  
The identification of such variants will require WGS analysis, but functional validation of found 
variants will be very challenging, and require extensive validation studies. 
1.2.6. Tandem repeats 
Expansion of tandem repeats are a cause of some monogenic conditions, such as the Fragile-
X syndrome, myotonic dystrophy and Huntington’s disease.  Most of the current sequencing 
technologies are not well suited to detect long repeats [30]. 
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2. PITFALLS IN INTERPRETATION AND VARIANT FILTERING 
Variant classification is one of the main challenges in contemporary genetics, as discussed 
already in chapter 3. Given the vast amount of very rare genetic variants, it remains often 
impossible to unambiguously interpret genetic variants. Classification according to certainty 
has been proposed, ranging from class 1 (certainly not functional) to class 5 (certainly 
pathogenic) [31]. However, this classification is still associated with much subjectivity. 
Moreover, it creates novel questions. For instance, which categories should be communicated 
to the patients, and under which circumstances? Should they be followed clinically or excluded 
from follow-up? Do we need to report unclassified variants (class 3), for which there is not 
sufficient evidence to classify them as either likely pathogenic or non-functional? 
Also, the knowledge in this field is growing rapidly, with novel genes being identified 
continuously for different phenotypes. This may leave the clinician with the feeling of always 
running behind, in the sense that the genetic test offered may not have incorporated the latest 
findings. Can we expect the genetic laboratory to regularly re-analyse the data in view of novel 
insights? And if we do, is this practically feasible and economically valid? 
Careful correlation of the genetic findings with the patient’s phenotype is crucial in correct 
interpretation. First, patients may carry more than one pathogenic mutation, which may 
explain why the phenotype wasn’t recognized clinically. In different series, patients with two 
separate de novo mutations were detected in 17/317 patients (5.3%) [8], 8/226 (3.5%) [32] 
and 101/2076 (4.9%) [33]. In one of the patients we studied, a SALL1 mutation was detected. 
However, it remains uncertain whether this is the sole explanation of her condition, as her 
phenotype is atypical and the ID is too severe compared to what is observed in other patients 
with Townes-Brocks syndrome.  
Also, under the hypothesis of a dominant cause of the disorder, variants found in a 
(supposedly) healthy parent will be discarded in a trio approach. For most severe syndromes, 
this is acceptable, since it is expected that these conditions occur de novo. However, many 
dominant syndromes exist with variable expressivity or even reduced penetrance. In these 
circumstances, a parent may be carrier of a pathogenic mutation with only mild or no 
manifestations. Examples include Noonan syndrome and Holt-Oram syndrome. It is therefore 
crucial that parents are also assessed clinically and counselled before genetic testing is 
initiated.  
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Another possible pitfall when filtering against inherited mutations are inherited mutations in 
imprinted genes, where the expression depends on the parental origin on which the mutation 
is located [34]. 
 
3. GUIDELINES FOR GENETIC TESTING IN PATIENTS WITH CHD 
From a clinical view, the indication for genetic testing can best be evaluated by classification 
of the patient according to a sporadic or familial occurrence and a syndromic or non-
syndromic appearance.  
 
3.1. Syndromic and sporadic 
This is the group where genetic testing is most frequently requested.  
It is now generally accepted that chromosomal microarray analysis is a first tier test given a 
high diagnostic yield of 15-20% in clinically unclassified syndromic patients [35-39]. Parental 
analysis can aid in the interpretation of a variant of unknown significance, but equally 
important is the message that parental karyotype analysis with FISH is required when a de 
novo duplication or deletion is found. This serves to exclude the small chance (2%) that one of 
them is carrier of a balanced insertional translocation of the fragment involved [40]. This 
situation is associated with a 50% recurrence risk, compared to a very low risk when this can 
be excluded (1% or less, due to possible germline mosaicism). 
WES is a second tier test, ideally in a trio design. The diagnostic yield of WES in cases with 
unknown syndromic CHD in the study by Homsy et al. [41] was 20%. This compares fittingly to 
other large studies in individuals with a developmental disorder, where the diagnostic yield 
varied from 16-50% [7, 42-44]. 
It is likely that in the future, WGS will replace both tests, since it will allow a comprehensive 
mutation scanning for both CNV’s and SNV’s.  
3.2. Syndromic and familial  
In this exceptional situation, microarray followed by WES is indicated as for sporadic 
syndromic cases. The optimal approach for WES depends on the suspected inheritance 
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pattern, which may be autosomal recessive or X-linked. However, in exceptional cases, the 
underlying cause will in fact be autosomal dominant, with gonadal mosaicism in one of the 
parents.  It has been common practice in clinical genetics to counsel parents of a child with a 
de novo dominant disorder for a low (1%) recurrence risk. This has recently been substantiated 
in genetic family studies, where in a quad approach (two parents and two children) 1% of all 
de novo mutations were shared by the two siblings [45] 
 
3.3. Familial non-syndromic 
Four studies have performed screening of a panel of genes in a cohort of familial CHD [46-49] 
(Table 1). 
Study N° genes N° families Selection N° solved Solved (%) 
Blue 2014 57 16 2 or more 5 31% 
Jia 2015 57 13 3 or more 6 46% 
El Malti 2016 4 154 2 or more 16 10% 
LaHaye 2016 WES 9 2 or more 3 33% 
 
Table 1. Comparison of 4 different studies in familial CHD with columns showing number of 
genes analysed, number of families included, selection of family based on number of 
individuals per family affected, number of families solved in total study and percentage of 
families solved in total study. 
Taken together, these results show that the chance of identifying the causal gene increases in 
large families. In most instances, the candidate gene corresponded to known genotype-
phenotype associations e.g. NOTCH1 in left outflow tract obstruction, TBX5 in atrial septal 
defects type II, NKX2.5 in septal defects, MYH6 in ASD II, and ELN in supravalvular stenosis of 
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peripheral pulmonary stenosis. These results indicate that testing a panel of known CHD genes 
is feasible in large CHD families with 3 or more affected individuals. However, as for many 
autosomal dominant disorders, genetic counselling is complicated by variable expressivity and 
reduced penetrance.  
3.4. Sporadic non-syndromic 
The majority of CHD patients occur sporadically and are non-syndromic. In this group, the 
contribution of genetic testing is limited.  
Several studies have shown an increased burden of rare CNV’s in cohorts of NS-CHD patients 
compared to the control population, on average about two fold increase [50]. Other studies 
reported an increased de novo incidence of CNV in 3.9%-15.4% of cases [51]. It is difficult to 
translate these findings to the clinic for a number of reasons. First, many studies did not 
include appropriate controls, but on average, a de novo CNV is found in 2% of the population. 
Second, different studies are difficult to compare, because of the inclusion of different types 
of CHD or different cut-off values for the size of a CNV (ranging from >100 kb to > 500 kb). 
Third, one of the complicating factors of such large cohort studies is that, in retrospect, many 
of the cases with a CNV were found to be in fact syndromic. Finally, given the occurrence or 
rare or de novo CNV’s in the normal population, the finding of a novel CNV in an individual 
with a NS-CHD does not implicate causality. With the exception of known pathogenic CNV’s, 
for most novel CNV’s it will not be possible to unambiguously assign causality [52].  
Before the advent of NGS, several studies have evaluated the incidence of mutations in single 
candidate genes in large cohorts of sporadic patients. Examples include NKX2-5, GATA4, and 
TBX20.   The overall conclusion is in line with the results from more recent trio exome studies 
in NS patients that de novo mutations are in fact very rare in sporadic NS-CHD. Homsy et al 
[41] reported a low incidence of excess de novo PTV in 2% in NS-CHD cases (compared to 20% 
of cases in S-CHD). Likewise, Sifrim et al. [11] also found a small excess of de novo protein 
truncating in CHD genes and of missense mutations in CHD genes and non-DD genes.  
As for CNV’s, also an excess of inherited rare SNV’s (minor allele frequency <1%) was observed 
in known CHD genes in NS-CHD, but not in S-CHD. This indicates that a small proportion of 
sporadic NS-CHD has an oligogenic cause, due to variants with a moderate effect and thus 
non-penetrance in one of the parents. In NS-CHD, because of reduced penetrance and variable 
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expressivity, patients can inherit mutations from an unaffected or mildly affected parent. Of 
interest, again an excess of inherited rare variants was observed in the genes not associated 
with CHD or DD, indicating that additional CHD genes remain to be identified. However, 
despite the statistically significant findings, the questions remains whether this is of clinical 
diagnostic interest as it only concerns a small proportion of cases (2% in the study of  Homsy 
et al.) [41]. This proportion further decreases when considering that in the study of Sifrim et 
al. one case had an inherited mutation in a gene associated with a recognisable cardiac 
phenotype (e.g. the ELN gene) and more than half had a mutation in a gene that typically 
causes a syndromic CHD, be it with variable expressivity: SOS1 and Noonan syndrome, FBN2 
and contractural arachnodactyly, SALL4 and Townes-Brocks syndrome, as well as COL1A1 and 
osteogenesis imperfecta. Therefore, from a diagnostic point of view, trio exome analysis in 
sporadic and apparently non-syndromic cases is unlikely to change the currently used empiric 
recurrence risks in the majority of cases, with the exception of a few very distinct types of CHD 
(ELN and SVAS/PPS, NKX2.5 and ASD2 with conduction disturbances).   
Thus, genetic testing in the majority of sporadic cases does not reveal a mutation, which is 
compatible with the generally accepted idea that sporadic NS-CHD has a multifactorial 
etiology.  
 
CLASSIFICATION OF CHD 
The distinction between these different categories is not always strict. First, certain CNV’s can 
present as either of these four categories.  There are CNV’s that are associated with an 
increased risk for various medical, developmental and psychiatric manifestations, with 
variable expressivity and reduced penetrance. These CNV’s are initially detected in an affected 
child, but can be inherited from a clinically unaffected parent.  The classical example in 
cardiology is the duplication in chromosome 1q21.1. This CNV is associated with Tetralogy of 
Fallot, and found in almost 1% of all ToF cases [51, 53].  Moreover, there is a risk for borderline 
intelligence, gross and fine motor disturbance, Autism Spectrum Disorder and increased 
prevalence of macrocephaly. Thus, the presentation can be either isolated or syndromic [54]. 
In addition, more than 80% of 1q21.1 duplications are inherited, from a parent with variable 
manifestations [55]. It can thus occur sporadically or familial. Other CNV’s that are associated 
to CHD include the 22q11.2 duplication syndrome [56, 57] and possibly the del15q11.2. 
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Counselling for such CNV’s is especially challenging with regard to recurrence risk of 
manifestations in a sibling or when detected antenatally. These are variants with a moderate 
effect, and are situated in a spectrum with monogenic and multifactorial at the ends. It is likely 
that in the future, WES and WGS will identify other genes that are susceptibility loci for CHD, 
either isolated or syndromic. These will present the same challenges in interpretation and 
counselling.  
 
Second, mutations in certain genes can be associated to either syndromic or non-syndromic 
CHD.  Obviously, this classification depends on a very careful and expert clinical evaluation. 
For instance, in a large series of so-called non-syndromic CHD, mutations are found in several 
syndromic genes [11, 58]. However, currently it is generally accepted that mutations in TBX5 
and JAG1 can be associated with either an isolated CHD as well as a syndromic [48, 59]. 
 
4. ECONOMIC ASPECTS OF NEXT GENERATION SEQUENCING 
Finally, translation of this novel NGS technology into the clinic still comes at a high financial 
cost. Developmental disorders caused by de novo mutations have an estimated prevalence of 
1/213 to 1/448 live births. Globally this would equate to almost 400,000 children being born 
per year with developmental disorders. For Belgium, with an annual birth rate of 
approximately 120.000, this means 270-560 children per year [60].  
Previous studies have indicated that first tier testing using microarray analysis is cost effective 
for individuals with unexplained ID [61]. For NGS, several studies suggest cost-effectiveness of 
WES performed at an early stage of the diagnostic odyssey in developmental disorders [62-
66], but other studies state that it is too early to say whether NGS technology offers value for 
money [67].  
Diagnostic testing including genetic testing are indicated when clinical utility is obvious: the 
results needs to be actionable, e.g. with regard to reproductive counselling, improved 
treatment options or prediction of outcome). However, clinical utility is difficult to define. In 
the field of clinical genetics, there is a strong tradition of believe in personal utility, i.e. the 
value of information about the cause of the disorder for the patient and, his family [68, 69]. 
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NGS is a great leap in accelerating our knowledge on genetics of CHD. This is already applied 
in research and diagnostic settings to the benefit of patients and their families. However, 
many limitations still exist. The next challenge is resolving the remaining gaps in our 
knowledge, and WGS will be the first next step in current and future studies. 
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DIE VROLIKE VLAM 
 
Dis die smorende vuur wat swaarkry 
en tog nie die kos kan gaarkry. 
 
Dis die vrolike vlam wat klap en kraak 
dis hy wat sy taak tot vermaaklikheid maak 
en sy swaarkry met lekkerkry klaarkry. 
 
- C.J. Langenhoven, Aan stille waters, 11 Julie 1932 
 
 
